 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 1 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
     
 
 
Venous stent for the Iliofemoral Vein Investigational clinical trial using the DUO ™ 
Venous Stent System (VIVID) 
Investigational Device: DUO ™ Venous Stent System  
Protocol Number: V-CA-0001 
Protocol Version: Rev. E 
Effective Date: April 23, 2021 
Study Sponsor: 
 Vesper Medical, Inc. 
640 Lee Road, Suite 101 
Wayne, Pennsylvania 19087  
United States of America 
484-892-6340 
 
This investigational protocol contains confidential informatio n for use by the principal investigators 
and their designated representatives participating in this clinical inve stigation. It should be held 
confidential and maintained in a secure location. It should not be co pied or made available for review 
by any unauthorized person or firm. 

 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 2 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
TABLE OF CONTENTS  
 Investigator Protocol Signature Page........................... ................................................... ...................... 9 
 Clinical Trial Synopsis ................................... ................................................... .................................... 10 
 Study Management Contact List ................................. ................................................... ..................... 17 
 Introduction .......................................... ................................................... ........................................... 18 
4.1. Background and Rationale ................................... ................................................... ................ 18 
4.2. Report of Prior Investigations .............................. ................................................... ................ 19 
 Investigational Device .................................. ................................................... .................................... 20 
5.1. Description ........................................ ................................................... ................................... 20 
5.2. Full Portfolio of DUO Venous Stent System Sizes ................... ................................................ 20  
5.3. Principles of Operation ................................... ................................................... ..................... 21 
5.4. Intended Use .......................................... ................................................... .............................. 22 
5.5. Future Considerations .................................... ................................................... ...................... 22 
 Clinical Trial Objectives .................................. ................................................... .................................. 23 
6.1. Primary Endpoints ..................................... ................................................... ........................... 23 
6.2. Secondary Efficacy Endpoints ................................ ................................................... .............. 23 
6.3. Observational Endpoints .................................. ................................................... .................... 24 
 Clinical Trial Design ................................... ................................................... ....................................... 25 
7.1. Anticipated Number of Subjects and Investigational Sites ................. .................................... 25 
7.2. Subject Population .................................. ................................................... ............................. 25 
7.3. Clinical Trial Duration & Follow-up ...................... ................................................... ................ 25 
7.4. Subject Selection ..................................... ................................................... ............................. 25 
7.4.1. Inclusion Criteria ..................................... ................................................... ......................... 25 
7.4.2. Exclusion Criteria ................................... ................................................... ........................... 27 
 Treatment Plan ........................................... ................................................... ..................................... 29 
8.1. Time and Events Schedule .................................... ................................................... ............... 29 
 Required Tests and Assessments ..................................... ................................................... ................ 31 
9.1. Laboratory Testing ................................... ................................................... ............................ 31 
9.2. SARS-CoV-2 Testing .................................. ................................................... ............................ 31 
9.3. Clinical Assessments ...................................... ................................................... ...................... 32 
9.3.1. Venous Disease State Classification ............................ ................................................... ..... 32 
9.3.2. Venous Ulcer Assessment .................................... ................................................... ............ 33 
9.3.3. Clinical-Etiology-Anatomy-Pathophysiology (CEAP) Classification ... .................................. 33 
9.3.4. Venous Clinical Severity Score (VCSS) – Pain Score .......................................... .................. 34 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 3 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
9.3.5. Villalta Score ....................................... ................................................... .............................. 34 
9.4. Questionnaires ........................................ ................................................... ............................. 35 
9.4.1. VEnous INsufficiency Epidemiological and Economic Study Quality of Life/Sy mptoms 
(VEINES-QOL/Sym) .......................................... ................................................... ................................. 35 
9.4.2. EQ-5D-3L ...................................... ................................................... .................................... 35 
9.5. Intravascular Ultrasound Imaging ................................ ................................................... ........ 35 
9.6. Venographic Imaging ................................... ................................................... ........................ 36 
9.7. Duplex Ultrasound Assessment ................................. ................................................... .......... 37 
9.8. X-ray Assessment ........................................ ................................................... ......................... 37 
 Screening Procedures ........................................ ................................................... .............................. 38 
10.1. Obtaining Informed Consent ................................ ................................................... ............... 38 
10.2. Screening Success and Failure Criteria ............................... ................................................... .. 38 
 Baseline Evaluation ...................................... ................................................... .................................... 40 
11.1. Baseline Assessments ..................................... ................................................... ..................... 40 
 Concomitant Medications .................................... ................................................... ............................ 41 
12.1. Pre-Procedural Medications ................................ ................................................... ................ 41 
12.2. Peri-Procedural Medications ................................ ................................................... ............... 41 
12.3. Post-Procedural Medications ............................. ................................................... .................. 41 
 Index Procedure ........................................ ................................................... ....................................... 43 
13.1. Index Procedure Baseline IVUS .............................. ................................................... .............. 43 
13.1.1. Preparation ....................................... ................................................... ............................... 43 
13.1.2. IVC Filter Placement ................................... ................................................... ...................... 43 
13.1.3. Baseline Venographic and IVUS Requirements ........................ .......................................... 43 
13.2. Pre-Dilation ..................................... ................................................... ..................................... 44 
13.3. Study Device Treatment ................................. ................................................... ...................... 44 
13.3.1. Enrollment (Intent-to-Treat) ............................ ................................................... ................ 44 
13.3.2. Treatment Recommendations ................................ ................................................... ......... 44 
13.3.3. Post-Study Device Treatment Measurements ................. ...................................................  44 
13.3.4. Final Treatment Results ................................... ................................................... ................ 45 
 Post-Procedure/Pre-Discharge ............................. ................................................... ........................... 46 
14.1. Required Assessments ........................................ ................................................... ................. 46 
 Required Follow-up Visits and Assessments .......................... ................................................... .......... 47 
15.1. 30-day Follow-up Visit (-2 days / +14 days post-Index Procedure) ...... .................................. 47 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 4 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
15.2. 6-month Follow-up Visit (–30 days post-Index Procedure) ........... ......................................... 47 
15.3. 12-month Follow-up Visit (–30 days post-Index Procedure) ............ ...................................... 47 
15.4. 24-month Follow-up Visit (–30 days post-Index Procedure) ............ ...................................... 48 
15.5. 36-month Follow-up Visit (–30 days post-Index Procedure) ............ ...................................... 49 
15.6. Unscheduled Visit ...................................... ................................................... .......................... 49 
15.7. Follow-up Visit Compliance ............................ ................................................... ...................... 50 
15.8. Subject Discontinuation and Replacement ...................... ................................................... .... 51 
 Risk/Benefit Assessment ......................................... ................................................... ......................... 52 
16.1. Risks............................................. ................................................... ......................................... 52 
16.2. Potential Benefits .................................... ................................................... ............................. 53 
16.3. Justification for Clinical Trial ............................ ................................................... .................... 53 
 Safety Events and Reporting Requirements ............................ ................................................... ........ 54 
17.1. Adverse Events ........................................ ................................................... ............................. 54 
17.2. Adverse Device Effects ................................... ................................................... ...................... 56 
17.2.1. ADE Reporting ..................................... ................................................... ............................. 56 
17.3. Serious Adverse Events .................................... ................................................... .................... 56 
17.3.1. SAE Reporting ..................................... ................................................... .............................. 57 
17.4. Major Adverse Events ................................... ................................................... ....................... 58 
17.4.1.  MAE Reporting ..................................... ................................................... ............................... 58 
17.5. Serious Adverse Device Effects ............................... ................................................... ............. 58 
17.5.1. SADE Reporting .................................... ................................................... ............................ 58 
17.6. Unanticipated Adverse Device Effects ............................. ................................................... .... 58 
17.6.1. UADE Reporting ................................... ................................................... ............................ 59 
17.7. Pregnancies ......................................... ................................................... ................................. 59 
17.8. Protocol Deviations and Protocol Violations ................ ................................................... ....... 59 
 Study Device Event Reporting ................................ ................................................... .......................... 61 
18.1. Device Deficiency .................................... ................................................... ............................. 61 
18.2. Device Malfunction ................................. ................................................... ............................. 61 
18.3. Device Returns ..................................... ................................................... ................................ 61 
 Statistical Methods and Considerations ............................... ................................................... ........... 62 
19.1. Introduction ....................................... ................................................... .................................. 62 
19.2. Analysis Groups ...................................... ................................................... .............................. 62 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 5 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
19.3. Enrollment Sample Size................................... ................................................... ..................... 63 
19.4. Study Success ........................................ ................................................... ............................... 63 
19.5. Administrative Reports and Interim Reports .......................... ................................................ 63  
19.6. Pooling Evaluation................................. ................................................... ............................... 64 
19.7. Handling of Missing Data .............................. ................................................... ....................... 64 
19.8. Summary of Baseline Demographics, Index Procedure Measurements, and Subject 
Compliance ........................................... ................................................... ............................................... 65 
19.9. COVID-19 Statistical Considerations ............................ ................................................... ........ 65 
19.10. Primary Safety Objective ............................. ................................................... ......................... 65 
19.11. Primary Efficacy Objective .............................. ................................................... ..................... 67 
19.12. Subgroup Summaries for Primary Endpoints ................. ................................................... ...... 70 
19.13. Secondary and Observational Endpoints ......................... ................................................... .... 70 
 Regulatory and Ethical Obligations ................................. ................................................... ................. 71 
20.1. Institutional Review Board / Ethics Committee Approval ............... ....................................... 71 
20.2. Informed Consent ....................................... ................................................... ......................... 71 
20.3. Protocol Amendment and Emergency Deviations ........................ .......................................... 71 
20.4. Subject Confidentiality ............................... ................................................... .......................... 72 
 Clinical trial Conduct .................................. ................................................... ...................................... 73 
21.1. Principal Investigator and Site Qualification ..................... ................................................... ... 73 
21.2. Principal Investigator and Site Training ........................ ................................................... ....... 73 
21.3. Clinical Monitoring ................................. ................................................... .............................. 73 
21.4. Device Accountability ................................ ................................................... ........................... 74 
21.5. Investigator Reports ................................... ................................................... .......................... 74 
21.6. Data Collection and Management ............................... ................................................... ........ 75 
21.7. Safety Monitoring .................................. ................................................... .............................. 75 
21.7.1. Data Safety Monitoring Board ............................ ................................................... ............. 75 
21.7.2. Clinical Events Committee ............................ ................................................... ................... 76 
21.8. Medical Monitoring .................................. ................................................... ........................... 76 
21.9. Central Core Laboratories ................................ ................................................... .................... 77 
21.10. Record Retention ................................... ................................................... .............................. 77 
21.11. Audits/Inspections ................................... ................................................... ............................ 78 
21.12. Study Termination (Stopping Rules) ....................... ................................................... ............. 79 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 6 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
21.13. Coverage of Subject Expenses ............................... ................................................... .............. 79 
21.14. Clinical Trial Reports ............................... ................................................... .............................. 79 
21.15. Publication Policies ............................. ................................................... ................................. 80 
21.16. Medicare Study Criteria ................................ ................................................... ....................... 80 
 Economic Analysis ....................................... ................................................... ..................................... 81 
 Study Definitions ...................................... ................................................... ........................................ 82 
 References .............................................. ................................................... ......................................... 89 
 
Table 1. List of Acronyms ................................... ................................................... ........................................ 7 
 
Figure 1. Duo Venous Stent System ................................ ................................................... ......................... 21 
Figure 2. Hybrid Stent ...................................... ................................................... ........................................ 22 
Figure 3. Extension Stent .................................... ................................................... ..................................... 22 
 
  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 7 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 
Table 1. List of Acronyms 
Acronym Definition 
ADE  Adverse Device Effect 
AE  Adverse Event 
aPTT Activated Partial Thromboplastin Time 
AT Acute Thrombotic 
BfArM Federal Institute for Drugs and Medical Devices 
BMI Body Mass Index 
CBC Complete Blood Count  
CDC Centers for Disease Control and Prevention 
CD-TLR Clinically Driven Target Lesion Reintervention 
CD-TVR Clinically Driven Target Vessel Reintervention  
CEAP Clinical-Etiology-Anatomy-Pathophysiology 
CEC  Clinical Events Committee 
CFV Common Femoral Vein  
CIV Common Iliac Vein  
COVID-19 Coronavirus Disease of 2019 
CPT Chronic Post Thrombotic 
CRF  Case Report Form 
CRO Clinical Research Organization 
CT Computed Tomography 
CVD Chronic Venous Disease 
CVI Chronic Venous Insufficiency 
DSA Digital Subtraction Angiography  
DSMB Data Safety and Monitoring Board 
DUS Duplex Ultrasound  
DVT Deep Vein Thrombosis 
EC Ethics Committee 
eCRF Electronic CRF 
EDC  Electronic Data Capture 
eGFR Estimated Glomerular Filtration Rate 
EIV External Iliac Vein  
EU European Union 
FAS Full-Analysis Set  
FDA  Food and Drug Administration 
GCP  Good Clinical Practice 
HIPAA Health Insurance Portability and Accountability Act  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 8 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
Acronym Definition 
ICF  Informed Consent Form 
ICH  International Conference on Harmonization 
IDE Investigational Device Exemption 
IFU  Instructions for Use 
INR International Normalized Ratio 
IRB  Institutional Review Board 
ISO International Organization for Standardization 
ITT Intent-to-Treat 
IVC Inferior Vena Cava 
IVUS Intravascular Ultrasound  
LTFU Lost to Follow-up 
MAE  Major Adverse Event 
NSAID Nonsteroidal anti-inflammatory drug 
NT Nonthrombotic 
OUS Outside the United States  
PE Pulmonary Embolism 
PG Performance Goal 
PI  Principal Investigator 
PIC  Subject Implant Card 
PP Per-Protocol 
PT Prothrombin time 
PTA  Percutaneous Transluminal Angioplasty 
PTS Postthrombotic Syndrome 
QOL Quality of Life 
RO Radiopaque  
SADE  Serious Adverse Device Effect 
SAE  Serious Adverse Event 
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2 
TLR  Target Lesion Reintervention 
TVR  Target Vessel Reintervention 
UADE  Unanticipated Adverse Device Effect 
VCSS Venous Clinical Severity Score 
WBC White Blood Cell  
 
 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 9 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 INVESTIGATOR PROTOCOL SIGNATURE PAGE 
 
STUDY TITLE: Venous stent for the Iliofemoral Vein Investigational clinical trial using the 
DUO ™ Venous Stent System ( VIVID ) 
 
CLINICAL TRIAL 
CENTER: _____________________________________________ 
 (Print name of study center) 
 
I, the undersigned, have read and understand the protocol specified above. As an Investigator, I 
understand that I am responsible for adhering to the terms of this protocol by ensuring  the safety of 
clinical trial subjects enrolled under my supervision and by providing the Sponsor wi th complete and 
timely information. In addition, I understand that all information pertaining to this clinical trial shall be 
held strictly confidential and I will ensure that the requirement for confidentiality is un derstood by all 
staff involved in this clinical trial. I agree to abide by the terms of this proto col and to maintain the 
procedures required to conduct this clinical trial in accordance with the Investigator Agreement, Good 
Clinical Practice, Declaration of Helsinki, 21 CFR Parts 50, 54, 56, and 812, ISO 14155, and any appl icable 
local regulations. 
 
 
___________________________________________________________________ 
SITE INVESTIGATOR – Print Name 
 
 
___________________________________________________________________ 
SITE INVESTIGATOR – Signature 
 
_______________________ 
DATE  
 
 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 10 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 CLINICAL TRIAL SYNOPSIS  
Study Title: Venous stent for the Iliofemoral Vein Investigational clinical trial using the DUO ™ 
Venous Stent System ( VIVID ) 
Study Design: This is a prospective, multi-center, single-arm, non-blinded clinical trial. 
Study Objective:  To investigate the safety and efficacy of the Vesper DUO Venous Stent System in the 
treatment of subjects presenting with iliofemoral occlusive disease as compared to 
a pre-defined performance goal (PG) established from published, peer reviewed 
scientific literature related to stenting of iliofemoral venous outflow obstructions.  
Study Device: The DUO Venous Stent System is manufactured by Vesper Medical, Inc. and 
consists of a primary hybrid stent designed for treating the iliac vein and an 
extension stent designed for extending treatment into the common femoral vein. 
Subjects may be treated with the hybrid stent alone or the hybrid stent and 
extension stent together. 
Intended Use:  The DUO Venous Stent System is intended for use in the iliac and common femoral 
veins for improving luminal diameter in symptomatic venous outflow obstructions .  
Subject 
Population: Subjects with nonmalignant iliofemoral venous outflow obstruction presenting with 
nonthrombotic (NT), acute thrombotic (AT) or chronic postthrombotic (CPT) disease 
pathogenesis will be selected for study participation. At least 20% of the total 
population must be enrolled in each group. Subjects must meet all inclusion criteria 
and not meet any of the exclusion criteria to be enrolled in the study. 
Regulatory 
Status: The DUO Venous Stent System will be limited by U.S. (Federal) law to 
investigational use only. 
Enrollment and 
Follow-up: Up to 160 subjects will be enrolled at up to 45 U.S. and International investigative 
sites. Each site can enroll a maximum of 32 subjects, establishing an enrollment cap 
at 20% of the total subject sample size. The follow-up period for enrolled subjects 
that receive at least one DUO Stent is 36 months. Subjects that are enrolled but do 
not receive at least one DUO Stent will be followed for 30 days and then exited 
from the study. 
Primary 
Endpoints: Safety:  Freedom from major adverse events (MAEs) at 30 days post index 
procedure, as adjudicated by the Clinical Events Committee (CEC) or Core 
Laboratory, including: 
▪ Device or procedure-related death 
▪ Device or procedure-related bleed at the target vessel and/or the 
target lesion or at the access site requiring surgical or endovascular 
intervention or blood transfusion of g2 units  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 11 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
▪ Device or procedure-related venous injury occurring in the target vessel 
and/or the target lesion or at the access site requiring surgical or 
endovascular intervention  
▪ Major amputation of the target limb  
▪ Clinically significant pulmonary embolism (PE), confirmed by CT 
angiography 
▪ Stent embolization outside of the target vessel 
▪ Presence of new thrombus within the stented segment 
Efficacy:  Primary patency of stented segment at 12 months defined as freedom 
from: 
▪ Duplex Ultrasound (DUS) core laboratory adjudicated occlusion or stenosis 
>50% within the stented segment. If site reported or core laboratory 
adjudicated DUS shows >50% stenosis or occlusion, confirmation by 
diagnostic intravascular ultrasound (IVUS) is required.  
▪ CEC adjudicated clinically driven target lesion reintervention (CD-TLR) 
defined as endovascular or surgical procedure for new, recurrent, or 
worsening symptoms and core lab adjudicated >50% stenosis or occlusion 
within the stented segment confirmed by diagnostic IVUS   
Secondary 
Efficacy 
Endpoints: ▪ Subject symptom relief via VCSS pain score at 12 months 
▪ Primary assisted patency at 12 months 
o Defined as freedom from DUS core laboratory adjudicated 
occlusion or stenosis >50% within the stented segment following a 
reintervention due to a >50% but <100% stenosis. If DUS shows 
>50% stenosis or occlusion, confirmation by diagnostic IVUS is 
required. 
▪ Secondary patency at 12 months 
o Defined as freedom from DUS core laboratory adjudicated 
occlusion or stenosis >50% within the stented segment following a 
reintervention due to 100% occlusion. If DUS shows >50% stenosis 
or occlusion, confirmation by diagnostic IVUS is required. 
Observational 
Endpoints: ▪ Device Success defined as: 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 12 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
(*Core 
Laboratory 
Adjudicated) o Successful deployment of the DUO Stent(s) at the intended target 
site, AND 
o Successful withdrawal of the delivery catheter(s) from the 
introducer sheath, AND 
o The DUO Stent remaining at the intended deployment location 
through completion of the index procedure as determined by the 
Principal Investigator (PI)  
▪ Lesion success defined as target lesion patency of f50% residual diameter 
or area stenosis of the stented segment at the completion of the 
procedure* 
▪ Procedural success defined as lesion success without the occurrence of CEC 
adjudicated major adverse events (MAEs) from the time start of the index 
procedure through discharge 
▪ Stent fracture via X-ray through 36 months* 
▪ Stent migration via X-ray through 36 months* 
▪ Stent embolization via X-ray or venogram through 36 months* 
▪ Primary patency of the stented segment via DUS at 24 and 36 months. If 
DUS shows >50% stenosis or occlusion, confirmation by diagnostic IVUS 
may be required.* 
▪ Primary assisted patency of the stented segment via DUS at 24 and 36 
months. If DUS shows >50% stenosis or occlusion, confirmation by 
diagnostic IVUS may be required.*   
▪ Secondary patency of the stented segment via DUS at 24 and 36 months. If 
DUS shows >50% stenosis or occlusion, confirmation by diagnostic IVUS 
may be required.*  
▪ Changes in the clinical CEAP Classification through 36 months 
▪ Changes in the EQ-5D-3L through 36 months 
▪ Changes in the Villalta Score through 36 months 
▪ Changes in the VCSS Pain Score at 24 and 36 months 
▪ Changes in the VEINES QOL/Sym Score through 36 months 
▪ CEC adjudicated MAEs post 30 days through 36 months  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 13 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
▪ CEC adjudicated CD-TLR through 36 months 
▪ CEC adjudicated clinically driven target vessel reintervention (CD-TVR) 
through 36 months   
▪ Venous Ulcer Assessment through 36 months 
Inclusion 
Criteria: 1. Males or non-pregnant, non-breastfeeding females g 18 years of age at the time 
of consent  
2. Subject is able and willing to provide written informed consent prior to 
receiving any non-standard of care, protocol specific procedures 
3. Female subjects of childbearing potential must have a negative pregnancy test 
within 7 days prior to treatment and must use some form of contraception 
(abstinence is acceptable) throughout the time of clinical trial exit 
4. Willing and capable of complying with all required follow-up visits 
5. Estimated life expectancy g1 year  
6. Subject is ambulatory (use of assistive walking device such as a cane or walker 
is acceptable) 
7. Body mass index (BMI) <45 
8. Clinically significant symptomatic venous outflow obstruction in one iliofemoral  
venous segment (one limb) per subject, is indicated for venoplasty and stenting, 
and meets at least one of the following clinical indicators: 
a. CEAP score g3  
b. VCSS pain score g2    
c. Suspected deep vein thrombosis (DVT) with symptoms occurring prior 
to receiving a DUO Stent 
9. Subject is willing and able to comply with PI recommendation for compression 
therapy, if required 
10. Presence of unilateral, non-malignant venous obstruction of the common 
femoral vein (CFV), external iliac vein (EIV), common iliac vein (CIV), or any 
combination thereof, defined as a g50% reduction in t arget vessel lumen 
diameter and confirmed by venographic or IVUS imaging. The cranial point of 
the obstruction may extend to the iliac vein confluence of the inferior vena 
cava (IVC) and the caudal point may be 2mm above either the inflow of the 
deep femoral (or profunda) or the lesser trochanter, whichever is most cranial  
11. Obstructive lesion(s) able to be treated with continuous stent coverage  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 14 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
12. Adequate inflow to the target lesion(s) involving at least a patent femoral or 
deep femoral vein and a landing zone in the CFV free from significant disease 
requiring treatment  
13. Reference vessel diameter is of adequate size to accommodate the appropriate 
size stent as measured by IVUS  
14. All vessels from insertion site through target vessel can accommodate a 9F or 
10F sheath, depending on the stent size used 
15. Ability to cross interventional devices through target lesion(s) 
16. In DVT subjects, successful treatment of acute thrombus must have occurred 
prior to receiving any DUO Stents for an underlying obstructive lesion. 
Successful treatment of acute thrombus is defined as reestablishment of 
antegrade flow with f30% residual thrombus (confirmed by venogram or IVUS) 
and freedom from bleeding and symptomatic pulmonary embolism (confirmed 
by imaging). After successful treatment of thrombus is confirmed, eligible 
obstructive lesion(s) can be treated with a DUO Stent during the same 
procedure. 
17. All subjects must undergo a SARS-CoV-2 test and have a negative test result 
within 8 days prior to the index procedure. If a SARS-CoV-2 test is unavailable 
due to institution policy, a test shortage, or if there is a delay in test results, the 
subject must complete the COVID-19 questionnaire and must have answered 
NO to all questions to be eligible for enrollment. A SARS-CoV-2 test will not be 
required for enrollment if a subject has received a complete cycle of an 
authorized COVID-19 vaccine or has documented evidence of a positive COVID-
19 antibody test and is asymptomatic and has no long-lasting effects (per PI  
discretion) from a prior COVID-19 infection.    
18. A measured temperature less than 99.5°F (37.5°C) on the day of the index 
procedure and no history of fever or feeling feverish within 14 days of the index 
procedure  
19. No prior history, within 60 days of the index procedure, of a SARS-CoV-2 
positive test, or COVID-19 symptoms 
Exclusion 
Criteria: 1. Target limb symptoms caused by peripheral arterial disease 
2. Presence of unresolved significant PE prior to use of the DUO Venous Stent 
System confirmed by chest CT. If subject has documented history of significant 
pulmonary embolism within the last 6 months, a chest CT is required to confir m 
significant pulmonary embolism is not currently present. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 15 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
3. Presence of IVC obstruction or target venous obstruction that extends into the 
IVC 
4. Presence of acute DVT located outside target limb 
5. Contralateral venous occlusive disease of the CFV, EIV, and/or CIV, with 
planned treatment f390 days after the index procedure 
6. Uncontrolled or active coagulopathy or known, uncorrectable bleeding 
diathesis  
7. Coagulopathy causing INR >2 which is not amenable to medical treatment 
8. Platelet count <50,000 cells/mm3 or >1,000,000 cells/mm3 and/or White blood 
cell (WBC) <3,000 cells/mm3 or >12,500 cells/mm3 
9. Uncorrected hemoglobin of f9 g/dL  
10. Subject is on dialysis or has an estimated glomerular filtration rate (eGFR) <30 
mL/min. In subjects with diabetes mellitus, eGFR <45 mL/min. 
11. History of Heparin Induced Thrombocytopenia 
12. Presence of known aggressive clotting disorders such as Lupus Anticoagulant 
Disorder, Antiphospholipid antibody syndrome, homozygous gene Factor V 
Leiden or Prothrombin gene abnormalities, Protein C and S deficiency or 
Antithrombin deficiency  
13. Known hypersensitivity or contraindication to antiplatelet therapy or 
anticoagulation, nickel, or titanium 
14. Contrast agent allergy that cannot be managed adequately with pre-medication 
15. Intended concurrent adjuvant procedure (except for venoplasty) such as 
creation of temporary arteriovenous fistula, femoral endovenectomy or 
saphenous vein ablation and/or saphenous vein stripping during the index 
procedure 
16. Subjects who have had any prior surgical or endovascular procedures to the 
target vessel. Note that subjects who have had successful catheter-directed or 
mechanical thrombolysis in the target vessel for DVT at least 90 days prior to 
the index procedure may be included  
17. Planned surgical or interventional procedures of the target limb (except 
thrombolysis and/or thrombectomy in preparation for the procedure or vena 
cava filter placement prior to stent implantation in subjects at high risk for 
pulmonary embolism) within 30 days prior to or 30 days after the index 
procedure  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 16 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
18. Planned surgical or interventional procedures for other medical conditions (i.e., 
not associated with the target limb) 30 days prior to or 30 days after the index 
procedure 
19. Previous venous stenting of the target limb, the IVC, or contralateral limb if 
stents extend into the IVC 
20. Iliofemoral venous segment unsuitable for treatment with available sizes of 
DUO Stent implants 
21. Lesions with intended treatment lengths extending into the IVC 
22. No safe landing zone at or above the profunda femoral confluence 
23. Participating in another investigational study in which the subject has not 
completed the primary endpoint(s) 
24. Has other comorbidities that, in the opinion of the Investigator, would preclud e 
them from receiving this treatment and/or participating in study-required 
follow-up assessments 
 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 17 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 STUDY MANAGEMENT CONTACT LIST 
Please see APPENDIX A  – Study Management Contact List  located at the end of this document. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 18 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 INTRODUCTION  
4.1. Background and Rationale 
Chronic venous insufficiency (CVI), an advanced stage of chronic venous disease, is a common problem  
occurring in approximately 1-5% of the adult population.  CVI can be caused by a nonthrombotic 
(primary) or postthrombotic (secondary) stimulus that involves reflux, obstruction, or a combination of 
both.1,2   
Initial treatment for CVI centers around wearing compression stockings or performing venous valv e 
repair.3  For subjects in which symptoms are not relieved, the dominant pathophysiolog ic component 
may be obstruction rather than reflux.  Previous estimations that obstruction is a major contribut or in 
only 10% to 20% of subjects with severe chronic venous disease are probably low. 4  One study reported 
that 80% of subjects with iliofemoral thrombosis show extrinsic iliac compression on CT venography.5 
The role of venous obstruction in the deep venous system is increasingly recognized as a m ajor cause of 
CVI, with obstructive lesions in the iliocaval segment being much more relevant than lesions in the c rural 
and/or femoral veins.6,7  Venous obstruction can occur as a result of different causes, including extrinsic 
compression because of malignancy or anatomic variants (May-Thurner) and acute or chronic DVT.8  
Nonthrombotic iliac vein obstruction occurs where the iliac vein is crossed by the ili ac or hypogastric 
artery, more commonly known as May- Thurner9s syndrome.9  Initial treatment for symptomatic acute 
DVT involves anticoagulation; 23-60% experience postthrombotic syndrome desp ite optimal 
anticoagulant therapy.10 
Endovenous treatment of iliofemoral stenosis or occlusion with angioplasty and stent placement has 
emerged as the procedure of choice to establish and maintain venous outflow.11  Venous stenting was 
first described in the late 1980s12 and is now recommended by a number of international guidelines as 
treatment for subjects with iliac or common femoral vein obstruction.13,14,15 
The American Venous and Lymphatic Society recommends venous balloon angioplasty and ste nting for 
treatment of nonthrombotic and postthrombotic iliac and common femoral ven ous obstructions in 
subjects with lower extremity pain or edema affecting quality of life (QOL) that cannot be palliated by 
compression.  Stenting is also recommended for subjects with impending or active lower extremity 
venous leg ulceration caused by obstruction.16  
Stent placement has a high technical success rate and is effective at restoring patency.17  Technical 
success of stent placement has been reported to be 84-93% in chronic postthrombotic iliac vein  
obstruction.18  Clinical improvement appears to be long lasting.19  Neglen reported on a group of 982 
subjects with chronic nonmalignant obstructive lesions of the femoroiliocaval vein that were stented 
under IVUS guidance .  Primary, assisted primary and secondary patency rates of 57%, 80%, and 86% 
were achieved at 6 years in thrombotic disease while nonthrombotic rates were 79%, 100%, and 100%, 
respectively.20 Other smaller studies have reported similar results.21,22,23,24,25,26  More recent data 
reported primary, assisted primary, and secondary patency rates of 93%, 96%, and 100%, respe ctively, 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 19 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
at 1 year, in the first 30 subjects treated with the Veniti Vici stent27 and 85% primary patency in the first 
20 subjects treated with the Zilver Vena stent.28 
Adverse Events (AEs) associated with venous stenting have been minimal.  The most c ommon 
complications include early (<30 days) and late thrombosis (1.5-3% and 5%, respectively).  Mortality is 
low, reported at 0-1%.29  Extension of the stent into the IVC is associated with contralateral iliac vei n 
occlusion 1% of the time.  However, failure to extend the stent into the IVC when n eeded may result in an 
ipsilateral restenosis or occlusion rate of 36%.30  Absolute contraindications listed for iliocaval stenting 
include uncorrectable coagulopathy and local or systemic infection.31 
In summary, stenting in chronic iliocaval obstruction is safe and effective.  Excell ent long-term results with 
respect to revascularization and symptom relief have been achieved.  Recanalization to treat venous 
claudication with venous stents suggests the highest probability of success.32,33 
The Vesper DUO ™ Venous Stent System is a new purpose-built stent system that will be studied for us e 
in treating iliac and common femoral vein obstructions due to either nonthro mbotic or postthrombotic 
etiology. 
4.2. Report of Prior Investigations 
This is the first investigation of the DUO Venous Stent System in humans.  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 20 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 INVESTIGATIONAL DEVICE  
5.1. Description 
The Vesper DUO Venous Stent System  consists of a portfolio of self-expanding venous stent 
configurations mounted on disposable delivery systems for improving luminal dia meter in 
symptomatic venous outflow obstructions. The portfolio approach includes delivery systems 
with either a hybrid venous stent implant or an extension venous stent implant, enablin g the 
clinician to custom tailor treatment in the iliofemoral venous anatomy based on disease 
patterns and severity. The hybrid stent design has varying mechanical characteristics such as 
radial force/crush resistance and flexibility along its length to target the varying dynami c loading 
conditions in the iliofemoral venous system related to the treatment of disease states i ncluding 
nonthrombotic iliac vein compression, May-Thurner syndrome, deep venous thrombosis and 
postthrombotic venous occlusion. The extension stent consists of a highly flexib le region with 
reinforcement rings at both ends. The hybrid stent can be used independently or in conjunction 
with the extension stent to personalize the treatment region. The Extension stent shall only be 
used in conjunction with the Hybrid stent.  
 
5.2. Full Portfolio of DUO Venous Stent System Sizes 
 
Stent Type Stent 
Diameter Stent Lengths Available Delivery System 
Size 
Extension 12mm 40mm, 60mm, 80mm, 
100mm, 120mm, 140mm 9F 
Extension 14mm 40mm, 60mm, 80mm, 
100mm, 120mm, 140mm 9F 
Extension 16mm 40mm, 60mm, 80mm, 
100mm, 120mm, 140mm 10F 
Hybrid 12mm 60mm, 80mm,100mm, 
120mm, 140mm, 160mm 9F 
Hybrid 14mm 60mm, 80mm, 100mm, 
120mm, 140mm, 160mm 9F 
Hybrid 16mm 60mm, 80mm, 100mm, 
120mm, 140mm, 160mm 10F 
Hybrid 18mm 60mm, 80mm, 100mm, 
120mm, 140mm, 160mm 10F 
 
 
 
 
 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 21 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
5.3. Principles of Operation 
FIGURE 1  below provides an overview of the Vesper DUO Venous Stent System . 
 
 
 
 
Figure 1. Duo Venous Stent System  
 
The delivery catheter has an effective length of 120cm. The Outer Braided Sheath (3), which 
constrains the stent implant, is bonded proximally to the Bifurcation Luer (5) within  the 
Transition sleeve (4). The Hemostatic Valve (7) is integrated proximally to the Bifurcation Luer. 
The Inner Core Shaft (8) slides within the Hemostatic Valve.  A soft, tapered Distal Tip (1) is 
bonded to the distal end of the Inner Core Shaft for ease of advancement in the blood vessel. 
Constrained within the Outer Braided Sheath the self-expanding Stent implant is positi oned on 
the Inner Core between two radiopaque (RO) Distal Inner Core Markers. A radiopaque Target 
Band (2) is located on the distal end of the Outer Braided Sheath.  
 
The catheter is flushed prior to the procedure through the side port (6) of the Bifurcation Lu er 
and the Guidewire Port (9). Stent implant positioning is achieved prior to deploy ment by using 
the RO Markers on the Stent implant ( FIGURE 2  and FIGURE 3 ) and the Target Band on the outer 
sheath.  During Stent implant deployment, the Hemostatic Valve is unlocked by rotating the 
valve counterclockwise.  The Stent implant is unsheathed by pinning the Proximal Inner Core 
Shaft and pulling back on the outer sheath.   
 
 
FIGURE 2  and FIGURE 3  below provide an overview of the Vesper DUO Venous Stent System , 
Hybrid and Extension Stents. 
 
 
 

 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 22 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
Figure 2. Hybrid Stent  
 
 
 
Figure 3. Extension Stent  
 
The self-expanding Nitinol (nickel- titanium) Hybrid stent is designed with a <High Crush 
Resistance= segment (11) at the cranial end to resist local focal crush associated with May-
Thurner Syndrome and other nonthrombotic iliac vein compressions, followed by a <Transition= 
segment (12) that transitions into a <Highly Flexible= segment  (13) to mitigate kinks during knee 
and hip flexion.  The caudal end of the Hybrid stent is designed with a <reinforcement ring = (14) 
to mitigate end crush of the stent.  Both the cranial and caudal ends of the Hybrid stent includ e 
Gold radiopaque markers (10), 4 markers per end.  
 
The self-expanding Nitinol (nickel- titanium) Extension stent is designed with a <Highly Flexible= 
(16) body to mitigate kinks during knee and hip flexion with <reinforcement rings = (15) on both 
ends to mitigate end crush of the stent.  Both the cranial and caudal ends of the Extension stent 
include Gold radiopaque markers (10), 4 markers per end.  
 
The Nitinol (nickel-titanium) stents self-expand upon deployment from the Delivery Cathet er 
(FIGURE 1 ) into the target vessel.  The self-expanding Nitinol (nickel-titanium) stents impart a 
radial outward force on the inner luminal surface of target vessel to establish patency. 
 
  
5.4. Intended Use 
The Vesper DUO Venous Stent System  is intended for use in the iliac and common femoral veins for 
improving luminal diameter in symptomatic venous outflow obstructions.  
 
5.5. Future Considerations  
It is anticipated that the DUO Venous Stent System with a handle delivery system will become av ailable 
during the clinical trial. Once available, a minimum of 5 subjects at up t o 5 study sites will be treated 
using the handle delivery system, irrespective of disease state.  

 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 23 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 CLINICAL TRIAL OBJECTIVES  
6.1. Primary Endpoints 
Safety:  Freedom from major adverse events (MAEs) at 30 days post index procedure, as adjudicated by 
the Clinical Events Committee (CEC) or core laboratory including: 
▪ Device or procedure-related death 
▪ Device or procedure-related bleed at the target vessel and/or the target lesion or at the 
access site requiring surgical or endovascular intervention or blood transfusion of g2 units  
▪ Device or procedure-related venous injury occurring in the target vessel and/or the target 
lesion or at the access site requiring surgical or endovascular intervention 
▪ Major amputation of the target limb   
▪ Clinically significant pulmonary embolism, confirmed by CT angiography 
▪ Stent embolization outside of the target vessel 
▪ Presence of new thrombus within the stented segment 
Efficacy: Primary patency of stented segment at 12 months defined as freedom from: 
• Duplex Ultrasound (DUS) core laboratory adjudicated occlusion or stenosis >50% wi thin the 
stented segment. If site reported or core laboratory adjudicated DUS shows >50% stenosis or 
occlusion, confirmation by diagnostic IVUS is required.  
• CEC adjudicated clinically driven target lesion reintervention (CD-TLR) defined as endovascular 
or surgical procedure for new, recurrent, or worsening symptoms and core lab adjudicated 
>50% stenosis or occlusion within the stented segment confirmed by diagnostic IVUS  
6.2. Secondary Efficacy Endpoints 
▪ Subject symptom relief via VCSS pain score at 12 months 
▪ Primary assisted patency at 12 months 
o Defined as freedom from DUS core laboratory adjudicated occlusion or stenosis >50%  
within the stented segment following a reintervention due to a >50% but <100% 
stenosis. If DUS shows >50% stenosis or occlusion, confirmation by diagnostic IVUS is 
required. 
▪ Secondary patency at 12 months 
o Defined as freedom from DUS core laboratory adjudicated occlusion or stenosis >50%  
within the stented segment following a reintervention due to 100% occlusion. If DUS 
shows >50% stenosis or occlusion, confirmation by diagnostic IVUS is required.  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 24 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
6.3. Observational Endpoints  
▪ Device Success defined as: 
o Successful deployment of the DUO stent(s) at the intended target site, AND 
o Successful withdrawal of the delivery catheter(s) from the introducer sheath, AND 
o The DUO Stent remaining at the intended deployment location through completion of  
the index procedure as determined by the Principal Investigator (PI)  
▪ Lesion success defined as target lesion patency of f50% residual diameter  or area stenosis of the 
stented segment at the completion of the procedure* 
▪ Procedural success defined as lesion success without the occurrence of CEC adjudicated major 
adverse events (MAEs) from the time start of the index procedure through discharge* 
▪ Stent fracture via X-ray through 36 months* 
▪ Stent migration via X-ray through 36 months* 
▪ Stent embolization via X-ray or venogram through 36 months*  
▪ Primary patency of the stented segment via DUS at 24 and 36 months. If DUS shows >50% 
stenosis or occlusion, confirmation by diagnostic IVUS may be required.* 
▪ Primary assisted patency of the stented segment via DUS at 24 and 36 months. If DUS shows 
>50% stenosis or occlusion, confirmation by diagnostic IVUS may be required.*   
▪ Secondary patency of the stented segment via DUS at 24 and 36 months. If DUS shows >50% 
stenosis or occlusion, confirmation by diagnostic IVUS may be required.*  
▪ Changes in the clinical CEAP Classification through 36 months 
▪ Changes in the EQ-5D-3L through 36 months  
▪ Changes in the Villalta Score through 36 months 
▪ Changes in the VCSS Pain Score at 24 and 36 months 
▪ Changes in the VEINES QOL/Sym Score through 36 months 
▪ CEC adjudicated MAEs post 30 days through 36 months  
▪ CEC adjudicated CD-TLR through 36 months 
▪ CEC adjudicated CD-TVR through 36 months  
▪ Venous Ulcer Assessment through 36 months 
*Core Laboratory adjudicated  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 25 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 CLINICAL TRIAL DESIGN  
This is a prospective, multi-center, single-arm, non-blinded clinical trial designed to i nvestigate the 
safety and efficacy of the Vesper DUO Venous Stent System as compared to a pre-defined performance 
goal (PG) established from published, peer reviewed scientific literature related to stenting of 
iliofemoral venous outflow obstructions. 
7.1. Anticipated Number of Subjects and Investigational Sites 
Up to 160 subjects will be enrolled at up to 45 U.S. and International investigative sites. Ea ch site can 
enroll a maximum of 32 subjects, establishing an enrollment cap at 20% of the total subject  sample size.  
7.2. Subject Population 
Subjects with nonmalignant iliofemoral venous outflow obstruction presenting with nonthr ombotic 
(NT), acute thrombotic (AT), or chronic postthrombotic (CPT) disease pathogenesis wi ll be selected for 
study participation.  At least 20% of the total population must be enrolled in each group. Sub jects must 
meet all inclusion criteria and not meet any of the exclusion criteria to be enroll ed in this clinical trial.  
7.3. Clinical Trial Duration & Follow-up 
The follow-up duration for each enrolled subject who receives a DUO Stent implant is 36 months. Any 
subject who is enrolled but does not receive at least one DUO Stent implant will b e followed for 30 days 
and then exited from the study (see Section 13.3.1 ). 
 
7.4. Subject Selection 
7.4.1.  Inclusion Criteria 
Subjects must meet all the following Inclusion Criteria. The response for each criterion belo w must be 
<Yes= :  
1. Males or non-pregnant, non-breastfeeding females g18 years of age at the time of consent  
2. Subject is able and willing to provide written informed consent prior to receiving any non-
standard of care, protocol specific procedures 
3. Female subjects of childbearing potential must have a negative pregnancy test within 7 days 
prior to treatment and must use some form of contraception (abstinence is acceptable) 
throughout the time of clinical trial exit 
4. Willing and capable of complying with all required follow-up visits 
5. Estimated life expectancy g1 year  
6. Subject is ambulatory (use of assistive walking device such as a cane or walker is acceptable) 
7. Body mass index (BMI) <45 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 26 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
8. Clinically significant symptomatic venous outflow obstruction in one iliofemoral  venous 
segment (one limb) per subject, is indicated for venoplasty and stenting, and meets at least 
one of the following clinical indicators: 
a. CEAP score g3 
b. VCSS pain score g2    
c. Suspected deep vein thrombosis (DVT) with symptoms occurring prior to receiving a 
DUO Stent 
9. Subject is willing and able to comply with PI recommendation for compression th erapy, if 
required 
10. Presence of unilateral, non-malignant venous obstruction of the common femoral vein 
(CFV), external iliac vein (EIV), common iliac vein (CIV), or any combination thereof, defi ned 
as a g50% reduction in target vessel lumen diameter and confirmed by venographic or IVUS 
imaging. The cranial point of the obstruction may extend to the iliac vein confluence of the 
inferior vena cava (IVC) and the caudal point may be 2mm above either the inflow of the 
deep femoral (or profunda) or the lesser trochanter, whichever is most cranial  
11. Obstructive lesion(s) able to be treated with continuous stent coverage  
12. Adequate inflow to the target lesion(s) involving at least a patent femoral or deep femoral 
vein and a landing zone in the CFV free from significant disease requiring treatment  
13. Reference vessel diameter is of adequate size to accommodate the appropriate size stent as 
measured by IVUS  
14. All vessels from insertion site through target vessel can accommodate a 9F or 10F sheath, 
depending on the stent size used 
15. Ability to cross interventional devices through target lesion(s) 
16. In DVT subjects, successful treatment of acute thrombus must have occurred prior to 
receiving any DUO Stents for an underlying obstructive lesion. Successful treatment of acute 
thrombus is defined as reestablishment of a ntegrade flow with f30% residual thrombus 
(confirmed by venogram or IVUS) and freedom from bleeding and symptomatic pulmonary 
embolism (confirmed by imaging). After successful treatment of thrombus is confirmed, 
eligible obstructive lesion(s) can be treated with a DUO Stent during the same procedure. 
17. All subjects must undergo a SARS-CoV-2  test and have a negative test result within 8 days 
prior to the index procedure. If a SARS-CoV-2 test is unavailable due to institution pol icy, a 
test shortage, or if there is a delay in test results, the subject must complete the COVID-19 
questionnaire and must have answered NO to all questions to be eligible for enrollm ent. A 
SARS-CoV-2 test will not be required for enrollment if a subject has received a compl ete 
cycle of an authorized COVID-19 vaccine or has documented evidence of a positive COVID-
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 27 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
19 antibody test and is asymptomatic and has no long-lasting effects (per PI di scretion) from 
a prior COVID-19 infection. 
18. A measured temperature less than 99.5°F (37.5°C) on the day of the index procedure and no 
history of fever or feeling feverish within 14 days of the index procedure  
19. No prior history, within 60 days of the index procedure, of a SARS-CoV-2 positiv e test, or 
COVID-19 symptoms 
 
7.4.2.  Exclusion Criteria 
Subjects must not meet any of the following Exclusion Criteria. The response for each criterion 
below must be <No=:  
1. Target limb symptoms caused by peripheral arterial disease 
2. Presence of unresolved significant pulmonary emboli prior to use of the DUO Venous Stent 
System confirmed by chest CT. If subject has documented history of significant pulmonary  
embolism within the last 6 months, a chest CT is required to confirm significant pulmonary  
embolism is not currently present. 
3. Presence of IVC obstruction or target venous obstruction that extends into the IVC 
4. Presence of acute DVT located outside target limb 
5. Contralateral venous occlusive disease of the CFV, EIV, and/or CIV, with planned treatment 
f390 days after the index procedure  
6. Uncontrolled or active coagulopathy or known, uncorrectable bleeding diathesis  
7. Coagulopathy causing INR >2 which is not amenable to medical treatment 
8. Platelet count <50,000 cells/mm3 or >1,000,000 cells/mm3 and/or White blood cell (WBC) 
<3,000 cells/mm3 or >12,500 cells/mm3 
9. Uncorrected hemoglobin of f9 g/dL  
10. Subject is on dialysis or has an estimated glomerular filtration rate (eGFR) <30 mL/min. In 
subjects with diabetes mellitus, eGFR <45 mL/min. 
11. History of Heparin Induced Thrombocytopenia 
12. Presence of known aggressive clotting disorders such as Lupus Anticoagulant Disorder, 
Antiphospholipid antibody syndrome, homozygous gene Factor V Leiden or Prothro mbin 
gene abnormalities, Protein C and S deficiency or Antithrombin deficiency  
13. Known hypersensitivity or contraindication to antiplatelet therapy or anticoagulation, nickel, 
or titanium 
14. Contrast agent allergy that cannot be managed adequately with pre-medication 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 28 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
15. Intended concurrent adjuvant procedure (except for venoplasty) such as creation of 
temporary arteriovenous fistula, femoral endovenectomy or saphenous vein ablation and/or 
saphenous vein stripping during the index procedure 
16. Subjects who have had any prior surgical or endovascular procedures to the target vessel. 
Note that subjects who have had successful catheter-directed or mechanical thrombolysis in 
the target vessel for DVT at least 90 days prior to the index procedure may be included  
17. Planned surgical or interventional procedures of the target limb (except thrombolysis and /or 
thrombectomy in preparation for the procedure or vena cava filter placement prior to stent 
implantation in subjects at high risk for pulmonary embolism) within 30 days prior to or  30 
days after the index procedure  
18. Planned surgical or interventional procedures for other medical conditions (i.e., not 
associated with the target limb) 30 days prior to or 30 days after the index procedure 
19. Previous venous stenting of the target limb, the IVC, or contralateral limb if stents extend 
into the IVC 
20. Iliofemoral venous segment unsuitable for treatment with available sizes of DUO Stent 
implants 
21. Lesions with intended treatment lengths extending into the IVC 
22. No safe landing zone at or above the profunda femoral confluence 
23. Participating in another investigational study in which the subject has not com pleted the 
primary endpoint(s) 
24. Has other comorbidities that, in the opinion of the PI, would preclude them  from receiving 
this treatment and/or participating in study-required follow-up assessments 
  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 29 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 TREATMENT PLAN 
8.1. Time and Events Schedule 
All subjects will receive the assessments at specific time points as listed below: 
Assessment 
Baseline1 
Index Procedure 
Post-Procedure/ 
Pre-Discharge* 
30-day 
(-2 days/+14 
Days)14 
6 
Month 
(–30 Days)14 
12 
Month 
(– 30 Days)14 
24 
Month 
(– 30 Days)14 
36 
Month 
(– 30 Days)14 
Unscheduled9,10 
Informed Consent X2         
Inclusion/Exclusion 
Criteria X X        
SARS-CoV-2 Test/COVID-
19 Questionnaire4 X3   X X X X X X 
Demographics, Medical 
History and Risk Factors X         
Brief Physical Exam 
(Height, Weight, Temp) X         
Serum Creatinine, eGFR, 
WBC, Platelet Count, 
Hemoglobin X        
 
Prothrombin Time (PT)/ 
International Normalized 
Ratio (INR)5  X  X      
 
Activated Partial 
Thromboplastin time 
(aPTT)6 X  X      
 
Urine or Blood 
Pregnancy Test7 X         
Venous Ulcer 
Assessment X   X X X X X X 
CEAP Classification  X    X X X X X 
Villalta Score X    X X X X X 
VCSS Pain Score X    X X X X X 
VEINES-QOL/Sym 
Questionnaire  X    X X X X X 
EQ-5D-3L Questionnaire X    X X X X X 
Concomitant 
Medications X X X X X X X X X 
Duplex Ultrasound 
(DUS)8,11    X X X X X  X 
Venogram11  X15         X12   X16   X16  X 
Intravascular Ultrasound 
(IVUS)11  X15        X12   X16   X16  X 
X-ray of Implanted 
Stent11      X X X  X 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 30 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
* Assessments are to be completed post-index procedure and prior to the su bject being discharged from the hospital/clinic. 
1 Assessments may be done up to 30 days prior to the index procedure, except for a p regnancy test and SARS-CoV-2 test  
2 Informed Consent may be obtained up to 30 days prior to index procedure. 
3 All subjects must undergo a SARS-CoV-2 test and have a negative result with in 8 days of the Index Procedure to be eligible for 
study inclusion. COVID-19 questionnaire is only required under certain circu mstances when SARS-CoV-2 testing is not 
possible. 
4 If a SARS-CoV-2 test is unavailable due to institution policy, a test sho rtage, or if there is a delay in test results, the subject 
must complete the COVID-19 questionnaire and answer NO to all questions to  be eligible for study treatment. If a SARS-CoV-
2 test is unavailable due to institution policy or a test shortage at the time o f any follow-up or unscheduled visits, the COVID-
19 questionnaire must be completed. A SARS-CoV-2 test will not be required  if a subject has received a complete cycle of an 
authorized COVID-19 vaccine or has documented evidence of a positive COVID-19 anti body test, is asymptomatic, and has no 
long-lasting effects (per PI discretion) from a prior COVID-19 infection. 
5PT/INR to be obtained only if a subject is on chronic warfarin therapy. 
6 aPTT to be obtained only if a subject is on chronic heparin therapy. 
7 Negative urine or blood pregnancy test is required for female subjects of chi ldbearing potential within 7 days of the index 
procedure. 
8 All scheduled DUS exams should be performed per the protocol establishe d by the core laboratory. If a DUS is non-diagnostic 
(per the imaging protocol), the site should make every effort to obtain a repeat exam withi n the visit window.  
9 Unscheduled tests and assessments should be completed prior to any interventional procedures to target limb. 
10 Unscheduled tests and assessments to be performed as clinically indicated.  
11 All imaging of the target limb acquired during scheduled visits or an interven tional procedure to the target limb (such as 
venogram, IVUS, DUS, or X-ray) should be submitted to the respective core laboratory wi thin 3 business days.  
12 Required if DUS suggests >50% stenosis or occlusion of the stented segme nt, or if the DUS is non-diagnostic or sub-optimal 
(i.e., due to obesity). If a follow-up venogram and/or IVUS is refused by the subject, thi s must be documented and will not be 
considered a protocol deviation. 
13 For the purposes of this study, all AEs, regardless of relatedness to the  study device and/or study device procedure, target 
limb, or underlying venous disease are required to be reported on the AE eCRF  and are considered <protocol reportable=. 
Please see Section 17  for more information on safety events and reporting requirements.  
14 Follow-up assessments (required at the 30- day visit and beyond) that cannot be performed due to a subject9s medical 
condition (i.e., amputation) will not be considered protocol deviations i f documentation of the medical condition is present in 
the subject9s medical records.  
15 To be performed both pre-and post-study device treatment as outlined in Sections 9.5 and 9.6 and as described in the core 
laboratory manuals. 
16 May be required if DUS suggests >50% restenosis or occlusion of the stented s egment and if the subject is presently 
symptomatic requiring a reintervention. If a follow-up venogram and/or IVUS is refused by t he subject, this must be 
documented and will not be considered a protocol deviation. 
 Adverse Event (AE) 
Assessment13  X X X X X X X X 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 31 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 REQUIRED TESTS AND ASSESSMENTS  
The tests and assessments described in this section are required at baseline and/or at various foll ow-up 
visits according to the Time and Events Schedule in Section 8.1 . 
9.1. Laboratory Testing 
Laboratory blood samples must be drawn pre-procedure but may not exceed 30 days  prior 
to the index procedure.  
Laboratory samples include:  
▪ Serum Creatinine, eGFR, WBC, Platelet Count, Hemoglobin  
▪ PT/INR (only if a subject is on chronic warfarin) 
▪ aPTT (only if a subject is on chronic heparin) 
▪ Pregnancy test (if female of childbearing potential) within 7 days prior to index 
procedure  
▪ SARS-CoV-2 test and/or COVID-19 questionnaire within 8 days prior to index  
procedure (not required if subject has received a COVID-19 vaccination or shows 
positive for COVID-19 antibodies per Inclusion 17) 
 
9.2. SARS-CoV-2 Testing 
It is required that all subjects undergo testing for the Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2) that results in the Coronavirus Disease 2019 (COVID-19) withi n 
8 days prior to the index procedure. The result of this test must be negative for the subject 
to be eligible for enrollment in this clinical trial. If the test is positive, the subjec t must be 
documented as a screen failure.  
A SARS-CoV-2 test will not be required if a subject has received a complete cycle of an 
authorized COVID-19 vaccine or has documented evidence of a positive COVID-19 antibody 
test and is asymptomatic and has no long-lasting effects from a prior COVID-19 infect ion. 
If a SARS-CoV-2 test is unavailable due to institution policy, a test shortage, or if there is a 
delay in test results, the subject must complete the COVID-19 questionnaire. If the subject 
answers NO to all questions on the questionnaire and meets all other inclusion/exclusi on 
criteria, the subject may be enrolled in this clinical trial. In the event that a subject is 
enrolled in this clinical trial without a SARS-CoV-2 test, the reason must be docum ented in 
the subject9s  study records and be able to be verified by the Sponsor in order to avoid a 
protocol deviation. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 32 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
All enrolled subjects that receive a DUO Venous Stent(s) must undergo a SARS-CoV-2 test at 
every follow-up visit as well as all unscheduled visits. If at any time a SARS-CoV- 2 test is 
unavailable, the COVID-19 questionnaire must be administered. If the results of this test are 
positive at any time throughout the duration of the clinical trial, this must be document ed 
as an adverse event. If at any time a subject does test positive, no further SARS-CoV-2 
testing is required.  Please see Section 17  for more information on safety events and 
reporting requirements. 
A SARS-CoV-2 test will not be required at follow-up if one of the following have o ccurred: 
1. Subject was enrolled under the vaccination and/or antibody requirements for 
Inclusion 17 
2. Subject has received a full cycle of an authorized COVID-19 vaccination 
3.  Subject has documented evidence of a positive COVID-19 antibody test and is 
asymptomatic and has no long-lasting effects from a prior COVID-19 infection 
9.3. Clinical Assessments 
9.3.1.  Venous Disease State Classification 
Subjects will be grouped and analyzed based on their pre-treatment disease etiology. The PI 
will determine Venous Disease State Classification by classifying the subject as 
nonthrombotic, acute thrombotic, or chronic postthrombotic based on the criteria outlined 
below. The Venous Disease State Classification will be documented accordingly in the 
subject9s source records and in EDC.  
1. Nonthrombotic group: 
• Symptomatic subjects with iliofemoral venous obstruction and no history of 
DVT 
• If complete obstruction/occlusion extends into the EIV or CFV without 
involvement of iliac veins, subject should be classified as chronic 
postthrombotic 
2. Acute thrombotic group: 
• First episode of acute symptomatic ipsilateral DVT f 14 days old  with 
venographic or IVUS evidence of acute clot and iliofemoral obstruction 
requiring stent placement 
• Successful clot removal required prior to stent placement  
• Prior to stent placement, if target lesion shows evidence of a chronic 
component, subject will be classified as chronic postthrombotic 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 33 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
3. Chronic postthrombotic group:  
• Total occlusion or stenosis of iliofemoral segments requiring stent 
placement with onset of symptoms more than 14 days ago 
• Any obstruction of iliofemoral segments with history of ipsilateral DVT 
within 2 years regardless of onset of symptoms 
 
9.3.2.  Venous Ulcer Assessment 
An assessment of existing and/or new venous ulcers is to be performed according to the 
Time and Events Schedule in Section 8.1 . Any pre-existing venous ulcers documented at 
Baseline will be followed until they are resolved or until the subject completes/is exited 
from the study. Any new venous ulcers that develop during follow-up will be do cumented 
and followed in the same manner. For all documented venous ulcers, the PI or Sub-
Investigator (Sub-I) will classify them as Healed, Improving, Unchanged, or Worsening as 
well as the location of each. If, at the time of any follow- up visit, a subject9s  venous ulcer is 
dressed and it is not advisable to remove the dressing per PI discretion, this should be 
clearly documented and will not be considered a protocol deviation. 
9.3.3.  Clinical-Etiology-Anatomy-Pathophysiology (CEAP) Classification 
The Clinical aspect of the CEAP classification will be used to categorize venous disease. The 
8Clinical9 signs of venous disease are those that are visible  and used to categorize the subject 
from C0 to C6. 
Clinical CEAP Classification 
Clinical 
Classification Description 
C0 No visible or palpable signs of venous disease 
C1 Telangiectasia or reticular veins 
C2 Varicose veins 
   C2r Recurrent varicose veins 
C3 Edema 
C4 Changes in skin and subcutaneous tissue secondary 
to chronic venous disease 
                    C4a Pigmentation or eczema 
          C4b  Lipodermatosclerosis or atrophie blanche 
          C4c Corona phlebectatica 
C5 Healed  
C6 Active venous ulcer  
         C6r Recurrent active venous ulcer 
 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 34 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
9.3.4.  Venous Clinical Severity Score (VCSS) – Pain Score 
The VCSS system is a scoring system used to categorize nine attributes of venous disease 
into levels of severity ranging from 0 (absent) to 3 (severe). For this study, only the Pain 
Score will be collected.   
Venous Clinical Severity Score (VCSS) – Pain Score 
Attribute Score Description 
Pain 
(presumes 
venous 
origin) Absent = 0 None 
Mild = 1 Occasional, not restricting activity or 
requiring analgesics 
Moderate = 2 Daily, moderate activity limitation, 
occasional analgesics 
Severe = 3 Daily, severe limiting activities or 
requiring regular use of analgesics 
 
9.3.5.  Villalta Score  
The Villalta Scale for post thrombotic syndrome (PTS) is a scoring system in which five 
symptoms and six clinical signs are categorized by severity ranging from 0 (absent) to 3 
(severe) as well as presence or absence of venous ulcer. A total score of 0 through 4 
indicates no PTS, a score of 5 through 14 indicates mild/moderate PTS and a score of 1 5 or 
greater or presence of venous ulcers indicates severe PTS. 
The Villalta Scale 
Symptoms Score  
(Absent=0, Mild=1, Moderate=2, Severe=3)  
Pain  
Cramps  
Heaviness  
Pruritus  
Paraesthesia  
Clinical Signs Score  
(Absent=0, Mild=1, Moderate=2, Severe=3)  
Pretibial edema  
Skin induration  
Hyperpigmentation  
Redness  
Venous ectasia  
Pain on calf compression  
Venous Ulcer Present or Absent 
Total Score*  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 35 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
*The total score is the sum of all scores for each symptom and clinical sign. A score of 0 throu gh 4 
indicates no PTS, a score of 5 through 14 indicates mild/moderate PTS and a score of 15 or greater 
or presence of venous ulcers indicates severe PTS.  
 
9.4. Questionnaires 
9.4.1.  VEnous INsufficiency Epidemiological and Economic Study Quality of 
Life/Symptoms (VEINES-QOL/Sym)  
The VEINES-QOL/Sym scale is a 26-item subject-reported measure that generates 2 separate 
summary scores for symptoms (VEINES-Sym) and quality of life (VEINES-QOL).  
• The VEINES-QOL summary score (25 items) is an estimate of the disease effect 
on a subject 9s quality of life 
• The VEINES-Sym summary score (10 items) measures the severity of physical 
symptoms.  
This questionnaire must be completed by the subject. Responses are evaluated on a 2-p oint 
to 7-point scale that rates intensity, frequency, or agreement.  
9.4.2.  EQ-5D-3L 
The EQ-5D-3L instrument includes five dimensions; mobility, self-care, usual activities,  
pain/discomfort, and anxiety/depression. They each have three levels of categorization. This 
questionnaire must be completed by the subject.  
9.5. Intravascular Ultrasound Imaging 
IVUS is a very important imaging modality used in conjunction with venography.  To so me, 
this is considered the new gold standard in venous imaging.  IVUS allows for direct imagi ng 
of the vein from an inside-out vantage point with high resolution reproduction of the vesse l 
lumen, vessel wall, and importantly, the extravascular structures in close proximity to the 
vein.  This is particularly useful for detecting iliofemoral compression syndrome, often 
caused by overriding iliac arteries or mass-effect from other nearby structures (tumors, 
aneurysms, etc.). Intraluminal filling defects such as acute or chronic thrombus, webs, or 
spurs are better imaged and identified with IVUS.  Additionally, accurate and reproducible 
direct measurements of vessel diameter (long and short axis) and cross-sectional areas can 
readily be obtained using IVUS. The typical technique is to insert the IVUS catheter though 
the lesion and then acquire images as the catheter is pulled back.  IVUS runs generally 
should begin in a normal segment of the vessel cranial to the lesion of interest and 
terminate in a normal segment caudal to the lesion.  It is important to perform a slow and 
steady pull back of the IVUS catheter. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 36 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
An IVUS run of the IVC, CIV, EIV, and CFV must be acquired both pre-treatment and post-
treatment.  Images must be acquired in DICOM format directly from the IVUS equipment for 
core laboratory analysis. 
IVUS is required at the index procedure, for any reinterventions, and if the 12-month site 
reported or core laboratory adjudicated DUS shows >50% stenosis or occlusion of the 
stented segment. In addition, IVUS may be required for the 24 or 36-month DUS shows 
>50% stenosis or occlusion of the stented segment and the subject is symptomatic requiring 
a reintervention. Operators will be trained on the IVUS protocol provided by the core 
laboratory. No test cases are required for IVUS. A comprehensive overview for IVUS 
acquisition requirements can be found in the core laboratory manual. 
 
9.6. Venographic Imaging 
Venography is an important modality for the assessment and treatment of iliofemoral 
compression syndrome.  A lower extremity vein caudal to the lesion, typically the po pliteal 
vein or mid femoral vein, is accessed and radiopaque iodinated contrast is injected. Images 
are then captured as the dye flows cranially under digital subtraction angiography (DSA).  
This allows for the assessment of stenosis of the veins from extrinsic 
compression/obstruction, and for the detection of acute thrombus and intrinsic vein defect s 
(webbing, spurs, etc.). Angiographic images are typically acquired in the AP view.  However, 
angulated views from the LAO or RAO projections are essential to add additional 
information about vessel narrowing or <pancaking=, especially when the st enosis is 
eccentric.  This is also useful if the AP view does not demonstrate a narrowing of the vessel.  
A lack of dye in a venous segment usually represents an occlusion.  In the presence of 
occlusion there are typically numerous collaterals clearly visualized on venograph y.   
A full venographic run of the IVC, CIV, EIV, and CFV must be acquired both pre-treatment 
and post-treatment.  For all venography runs, a radiopaque or marker pigtail catheter 
should be utilized. This allows for accurate lesion length determination by the core 
laboratory.  Images must be acquired in DICOM format with and without DSA. Full 
venographic runs, not only still frames, are required for core laboratory assessment. 
Full venographic assessment must include the femoral vein, iliac veins, renal veins, and  IVC 
at the index procedure, for any reinterventions, and if the 12-month site reported or co re 
lab adjudicated DUS shows >50% stenosis or occlusion of the stented segment. In addition, 
venography may be required for the 24 or 36-month DUS shows >50% stenosis or occlusio n 
of the stented segment and the subject is symptomatic requiring a reintervention. 
Operators will be trained on the venography protocol provided by the core laboratory. No 
test cases are required for venography. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 37 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
A comprehensive overview for abdominal venography acquisition requirements can be 
found in the core laboratory manual. 
9.7. Duplex Ultrasound Assessment 
Abdominal/pelvic venous DUS is accepted as an effective method for diagnosis and follow 
up of iliofemoral obstruction syndrome and DVT. DUS combines spectral Doppler technolog y 
in addition to B-mode imaging to allow visualization of blood flow pattern abno rmalities 
within the Iliofemoral veins in the presence of DVT or obstruction. Increased velocities 
associated with lumen narrowing can be visualized with spectral and color Doppler.  B-mode 
cross-sectional and longitudinal imaging of diameters can also assess obstruction and 
extrinsic compression. A lack of color fill and B-mode visualization of thrombus can ind icate 
DVT. 
B-Mode, Color Doppler, and Spectral Doppler are required at the target vessels: IVC, CIV, 
EIV, and CFV.  Color and Spectral Doppler B-Mode diameters are required at the narrowest 
point (lesion) of the target vessel and at a normal reference level taken caudal to the lesion. 
Velocity measurements are required at the narrowest point (lesion) of the target vessel and 
at a normal reference level taken caudal to the lesion. 
Abdominal Venous DUS is required at the 30-day, 6-month, 12-month, 24-month, and 3 6-
month follow up visits.  Operators will be trained on the DUS protocol provided by the core 
laboratory. Each site is required to submit a test DUS exam to the core laboratory prior t o 
performing any study related DUS exams. 
A comprehensive overview for DUS acquisition requirements can be found in the core 
laboratory manual.  
 
9.8. X-ray Assessment 
An X-ray assessment will be performed at the 12-month, 24-month, and 36-month follo w-up 
visits to assess the DUO Stent(s)9  implant integrity for all subjects in whom at least one DUO 
Stent was placed during the index procedure.   
A comprehensive overview of procedural requirements for X-ray assessments can be found 
in the core laboratory manual.   
In Europe, the only medical procedure that may be considered a deviation from routine 
medical care are the X-rays performed during the 12, 24, and 36-month follow- up visits. The 
X-rays are performed to assess stent fracture and migration rates.  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 38 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 SCREENING PROCEDURES  
All subjects presenting to the institution with a suspected iliofemoral venous outflow obstruction will be 
screened for initial eligibility. A trained member of the research team shall perform a preliminar y 
evaluation of the potential subject9s medical history and screen for initial eligibility.  Only assessments 
consistent with the institution 9s standard of care may be performed prior to obtaining a signed consent 
form. If during pre-screening, a subject is found to meet one or more exclusion criteria,  or does not 
meet one or more inclusion criteria, the subject would be considered a pre-screen failure. The re ason 
for pre-screen failure must be documented in the screening log and no further action is required . 
 
If a subject is not a pre-screen failure, the subject is eligible to move forward with the screening and 
informed consent process.  Qualified and trained research staff listed on the Site Delegation of Auth ority 
Log will approach the subject and initiate the informed consent process.  
 
10.1. Obtaining Informed Consent 
All sites shall comply with 21 CFR 50, provisions of International Conference on Harmonizati on (ICH) E6 
Good Clinical Practices (GCPs), local institutional review board (IRB)/ethics committe e (EC) policies and 
all applicable local regulations for obtaining informed consent. Prior to obtaining informed consent, the 
PI or designee will thoroughly explain the nature and purpose of the study to the subj ect. The PI or 
designee will document the informed consent process in the subject9s source records and use the most 
current IRB/EC approved informed consent form (ICF) for each subject prior  to any study-specific 
screening/baseline tests or procedures being performed.  This does not include those pr ocedures or 
tests that are completed in the normal course of the subject9s non -study related care and that are done 
prior to undergoing the study procedure, but shall include previously performed tests that may need to 
be repeated to determine eligibility.   
 
All subjects shall possess the ability to understand the information contained in the in formed consent 
form. Subjects will have the study procedures explained in a manner as non-technical as possible, 
including the risks, benefits, and follow-up requirements. If the subject agrees to participate  in this 
study, the subject will be required to sign and date the ICF. If a subject possesses the ability  to 
understand the informed consent process and participation in study, but due to physical inabi lity cannot 
sign the ICF, an impartial witness may sign the ICF on behalf of the subject. Non-English-speaking  
subjects may only be enrolled if they sign an IRB/EC approved and certified translated informed con sent 
form that has been IRB/EC approved and is reflective of his/her spoken language. 
 
Once all required parties have signed the ICF, the subject will receive a copy of their signed informed 
consent form for his/her records. 
 
10.2. Screening Success and Failure Criteria 
Final eligibility of a subject will be confirmed during the Index Procedure. Subj ects must provide prior 
informed consent no greater than 30 days prior to the index procedure. If 30 days have passed since the 
subject signed an informed consent form, the subject should be re-consented. Every effort will be made 
to ensure subject eligibility prior to enrollment. If the subject meets all the inclusion c riteria and none of 
the exclusion criteria after pre-enrollment angioplasty, the subject will be considered eligib le for 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 39 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
enrollment. If at any point prior to or just after pre-enrollment angioplasty, but prior to the D UO stent 
system being advanced through the introducer sheath, an exclusion criterion is met and/or an in clusion 
criterion is not met, the subject will be deemed a screen failure. No further follow-up will be requ ired 
for these subjects; however, the following details will be documented in the subject9s source records:  
• Documentation that the subject is a screen failure 
• Documentation of the inclusion/exclusion criteria that was met and/or not met, with 
clarification provided as necessary 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 40 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 BASELINE EVALUATION  
11.1. Baseline Assessments 
The following assessments will be performed during baseline evaluation.  These e xaminations and 
tests will be used both to screen for eligible subjects and to provide baseline information for those 
subjects who meet study criteria. All assessments must be completed no more than 30 days prior to 
the subject undergoing the index procedure, except for the urine or blood pre gnancy test and the 
SARS-CoV-2 test and/or COVID-19 questionnaire. 
The urine or blood pregnancy test is required for female subjects of childbearing potential and must 
be completed no more than 7 days prior to the index procedure. The SARS-CoV-2  test may be required 
(See Inclusion 17) and must be completed no more than 8 days prior to the index  procedure. The 
result of both tests must be negative for the subject to be eligible for enrollment  in this clinical trial. 
A COVID-19 questionnaire may be used in place of a SARS-CoV-2 Test under certai n conditions. See 
Section 9.2 SARS-CoV-2 Testing  for more details. 
▪ Informed Consent  
▪ SARS-CoV-2 Test, if required per Inclusion 17 
▪ Assessment of Inclusion/Exclusion Criteria 
▪ Demographic information and medical history including risk factors  
▪ Brief physical examination  
o Including height and weight 
▪ Serum Creatinine, eGFR, WBC, Platelet Count, Hemoglobin 
▪ PT/INR (only if a subject is on chronic warfarin) 
▪ aPTT (only if a subject is on chronic heparin) 
▪ Urine or blood pregnancy test (required for females of childbearing potential only) wi thin 7 days 
prior to index procedure  
▪ Venous Ulcer Assessment 
▪ CEAP Classification  
▪ VCSS Pain Score  
▪ Villalta Score 
▪ VEINES-QOL/Sym Questionnaire 
▪ EQ-5D-3L Questionnaire  
▪ Review of Concomitant medications 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 41 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 CONCOMITANT MEDICATIONS  
In addition to the procedural medications described in the sections below, reportable medications 
to be recorded in the electronic Case Report Form (eCRF) are medications taken by the subj ect to 
treat their cardiovascular disease, including antithrombotics (antiplatelets, anticoagulants), 
antibiotics, NSAIDs, steroids, diuretics, calcium channel blockers, and statins. These medicatio ns will 
be captured at baseline through study completion and include prior ongoing or new use o f the 
medications mentioned in this section (either prescription or over the counter). 
In addition, all COVID-19 vaccinations received (prior to or after enrollment) will be rec orded in the 
eCRF. 
The following antiplatelet and anticoagulation regimen described in Sections 12.1, 12.2, and 12.3 
below,  is required, unless otherwise dictated by Institution or PI standard of care. If an alternative 
antiplatelet and anticoagulation regimen is required per Institution or PI, the regimen must  be 
documented prior to the first subject being enrolled. This alternative antiplatelet and 
anticoagulation regimen will be used to monitor pre-procedure, peri-procedure, and post-pro cedure 
medication compliance. Non-compliance with the documented antiplatelet and anticoagulatio n 
regimen will be considered a protocol deviation. If non-compliance is deemed medically  necessary 
for the patient9s safety and /or well-being, the reason must be documented, and the non-compliance 
will not be considered a protocol deviation.  
12.1. Pre-Procedural Medications 
Pre-procedural anticoagulation should be stopped if required by the PI or Institution.  
Subjects taking warfarin prior to the index procedure with a pre-procedural INR >2 due to 
coagulopathy (on the day of the index procedure) are still eligible for study devic e treatment subject 
to the approval of the PI. Subjects on antiplatelet therapy should stop, if required by the Institution 
or PI.  
 
12.2. Peri-Procedural Medications 
Full therapeutic anticoagulation is required for all subjects for the duration of the index procedure. 
The anticoagulation regimen should follow the site9s standard anticoagulation protocol  and must be 
documented in the subject 9s study records.  
 
12.3. Post-Procedural Medications 
For all subjects, institute full anticoagulation within 4 hours following the comple ted index 
procedure and follow the below regimen. Start time of full anticoagulation should be do cumented. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 42 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
Enoxaparin for the first 30 days post-procedure. After this time, continue full anticoagulati on with 
an oral anticoagulant. If warfarin is used, an INR of 2.0-3.0 with appropriate bridging therapy  is 
required. A direct oral anticoagulant, such as apixaban, dabigatran, rivaroxaban, or edoxaban can be 
used instead of warfarin. 
 
The minimum anticoagulation treatment durations are: 
▪ 3 months for nonthrombotic subjects 
▪ 12 months for thrombotic subjects 
▪ Long-term for subjects with thrombophilia 
Concomitant antiplatelet therapy with aspirin or thienopyridine class drugs may also be used at th e 
discretion of the PI. Due to the high risk of bleeding, dual antiplatelet therapy in add ition to 
anticoagulation is not recommended unless deemed appropriate by the PI. Antiplatelet therapy can 
be considered after anticoagulation therapy is discontinued. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 43 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 INDEX PROCEDURE  
All imaging-related inclusion/exclusion criteria are based on the P I9s assessment at the time of the 
Index Procedure.  
13.1. Index Procedure Baseline IVUS 
Final eligibility of all subjects will be confirmed using the Index Procedure Baseli ne IVUS. The Index 
Procedure Baseline IVUS must be performed during the index procedure in order to assess baseline 
imaging-related eligibility for inclusion as described in Section 13.1.3  below. Both the baseline 
venogram and IVUS are to be performed as per guidelines established by the independent core 
laboratory. Baseline venograms performed for all enrolled subjects will be reviewed by th e core 
laboratory as outlined in the venographic core laboratory protocol. 
All data that are required to be recorded during the index procedure are reflected in the index 
procedure interval eCRFs within the EDC. Required measurements and data listed in the following 
sections are not exhaustive of all data that is required. Therefore, the required data should be 
reviewed in advance of the procedure to ensure it is understood and captured appropriately. The 
electronic Case Report Form (eCRF) Completion Guidelines contain instructions for data entry and 
should be referenced, as necessary. 
13.1.1.  Preparation 
Procedural techniques will be in accordance with the institutional standard of care for 
iliofemoral venoplasty and stenting. 
All subjects should receive the appropriate anticoagulant therapy per Section 12 .  
13.1.2.  IVC Filter Placement 
IVC filter placement is not recommended but is ultimately at the discretion of the PI in 
circumstances such as floating thrombus in iliocaval segments or if there is planned use of 
mechanical thrombectomy in the presence of acute thrombus. In all cases, the IVC filter should 
be removed as soon as deemed safe by the PI. Confirmation of successful placement and  
removal of the IVC filter should be documented in the source documents and the eCRF. 
13.1.3.  Baseline Venographic and IVUS Requirements 
Baseline venographic and IVUS measurements of the target lesion and target vessels (visual  
estimate) shall be captured to determine eligibility and include, but are not limited to, the  
following: 
▪ Target lesion(s) details including vessel location(s), lesion length(s), and pre-P TA % 
reduction in target vessel lumen diameter 
▪ Indication for stenting and final disease state classification (acute DVT, nonthrombotic, 
chronic postthrombotic)   
▪ Reference vessel diameter(s)  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 44 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
▪ Inflow venous patency (if patency of profunda cannot be confirmed by venogram or 
IVUS, pre-operative DUS findings may be used to confirm) 
▪ Absence of thrombus and/or successfully treated thrombus for acute DVT subjects 
13.2. Pre-Dilation 
Please refer to the Instructions for Use (IFU) for detailed instructions regarding Pre-dilation inflati on 
recommendations. It is recommended that pre-dilation equivalent to the size of the intended s tent 
be performed. 
Pre-dilation balloon-related details will be recorded and include, but are not limited  to, the 
following: balloon name/manufacturer and balloon size, max pressure, inflation durati on at max 
pressure, and max inflation diameter across all inflations. 
13.3. Study Device Treatment 
Subjects who meet all inclusion criteria, and who do not meet any exclusion criteria wi ll be deemed 
eligible for Study Device Treatment. 
13.3.1.  Enrollment (Intent-to-Treat) 
A subject is defined as intent-to-treat (ITT) and officially enrolled in the study once the DUO 
Venous Stent System is advanced through the introducer sheath.   
Subjects in whom no DUO Stent implant is placed will be exited after 30 days.  Sub jects in whom 
at least one DUO Stent implant is placed will be followed for 36 months.   
The per-protocol (PP) population will be defined as ITT subjects with evaluable data that have 
met the definition for device success, excluding subjects with major deviations, such as those 
who meet criteria for a protocol violation(s), as determined by the Sponsor . 
13.3.2.  Treatment Recommendations 
Please refer to the IFU for detailed instructions regarding recommended criteria for use of the 
study device and stent sizing. IVUS is required for stent sizing. 
NOTE: When overlapping study devices, there should be no more than 2mm of diameter 
difference between devices. 
13.3.3.  Post-Study Device Treatment Measurements  
The following information should be recorded Post-Study Device Treatment: 
▪ Assessment of successful introduction, deployment, and withdrawal with the stent 
remaining in the intended location through completion of the procedure 
▪ Number and type of DUO Venous Stent Systems used to treat subject and associated lot 
number(s) as well as number of stents deployed 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 45 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
▪ Vessel location and size of each deployed DUO Stent 
13.3.4.  Final Treatment Results  
The following information should be recorded after post-dilation and upon completio n of index 
procedure and includes but is not limited to: 
▪ Adjunctive procedures performed and outcomes 
▪ Study Device Procedure Time (defined as the time the first DUO Venous Stent System is 
advanced through the introducer sheath to the time of withdrawal of the last balloon 
catheter) 
▪ Adverse event/device event occurrence 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 46 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 POST-PROCEDURE /PRE-DISCHARGE  
All subjects will be assessed post-procedure prior to discharge (Pre-Discharge) and shall receive a 
medical regimen for the medications required post-procedure per Section 12 . All study medications 
shall be captured in the eCRF. 
14.1. Required Assessments  
Assessments required post-procedure/pre-discharge include the following: 
▪ Adverse event assessment  
▪ Concomitant medication review 
▪ PT/INR (only for subjects on chronic warfarin)* 
▪ aPTT (only for subjects on chronic heparin)* 
* If a subject is on chronic warfarin or chronic heparin, they may be discharged before lab results 
from PT/INR or aPTT tests are obtained.  
All subjects receiving treatment with a DUO Stent implant should be provided with t he DUO Stent 
System Subject Implant Card (PIC). The PIC is designed for the subject to carry alo ng with their 
insurance cards. This PIC is to be completed by the designated research personnel to include 
information pertaining to the DUO Stent(s) including the model, lot number and vess el location of 
the implanted DUO Stent(s) and the date of the index procedure. The card also provide s 
manufacturer information and MRI Compatibility. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 47 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 REQUIRED FOLLOW -UP VISITS AND ASSESSMENTS  
All subjects will be required to return for clinic follow-up visits as outlined in Section 8.1 and in the 
sections below.  
In the event of a public health crisis, a global pandemic, a natural disaster, or any other event whi ch 
would preclude research sites from conducting research or restrict subject s9 ability to attend follow -up 
visits, guidance will be provided by the Sponsor regarding visit windows.  
15.1. 30-day Follow-up Visit (-2 days / +14 days post-Index Procedur e) 
The following assessments are required to be performed at the 30-day follow-up visit: 
▪ SARS-CoV-2 Testing (if required per Section 9.2) 
▪ DUS 
▪ Venous Ulcer Assessment 
▪ Adverse event assessment  
▪ Review of concomitant medications  
15.2. 6-month Follow-up Visit (–30 days post-Index Procedure) 
The following assessments are required to be performed at the 6-month follow-up visit: 
▪ SARS-CoV-2 Testing (if required per Section 9.2) 
▪ Venous Ulcer Assessment 
▪ CEAP Classification 
▪ Villalta Score 
▪ VCSS Pain Score 
▪ DUS  
▪ VEINES-QOL/Sym Questionnaire 
▪ EQ-5D-3L Questionnaire 
▪ Adverse event assessment  
▪ Review of concomitant medications 
15.3. 12-month Follow-up Visit (–30 days post-Index Procedure) 
The following assessments are required to be performed at the 12-month follow-up visit: 
▪ SARS-CoV-2 Testing (if required per Section 9.2)  
▪ Venous Ulcer Assessment 
▪ CEAP Classification 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 48 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
▪ Villalta Score 
▪ VCSS Pain Score 
▪ DUS  
▪ X-ray of implanted stent(s) 
▪ VEINES-QOL/Sym Questionnaire  
▪ EQ-5D-3L Questionnaire  
▪ Adverse event assessment  
▪ Review of concomitant medications  
▪ Follow-up venogram and IVUS are required if DUS suggests >50% stenosis or occlusion of 
the stented segment, or if the DUS is non-diagnostic or sub-optimal (i.e., due to obesity). If a 
follow-up venogram/IVUS is refused by the subject, this must be documented and will not 
be considered a protocol deviation and the DUS will be used if available.  
15.4. 24-month Follow-up Visit (–30 days post-Index Procedure) 
The following assessments are required to be performed at the 24-month follow-up visit: 
▪ SARS-CoV-2 Testing (if required per Section 9.2) 
▪ DUS 
▪ X-ray of implanted stent(s) 
▪ Venous Ulcer Assessment 
▪ CEAP Classification 
▪ Villalta Score 
▪ VCSS Pain Score 
▪ VEINES-QOL/Sym Questionnaire  
▪ EQ-5D-3L Questionnaire  
▪ Adverse event assessment  
▪ Review of concomitant medications  
▪ Follow-up venogram and IVUS may be required if DUS suggests >50% stenosis or occlusi on 
of the stented segment, and if the subject is symptomatic requiring a reintervention. If a 
follow-up venogram and/or IVUS is refused by the subject, this must be documented and 
will not be considered a protocol deviation and the DUS will be used if available.  
 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 49 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
15.5. 36-month Follow-up Visit (–30 days post-Index Procedure) 
The following assessments are required to be performed at the 36-month follow-up visit:  
▪ SARS-CoV-2 Testing (if required per Section 9.2) 
▪ DUS 
▪ X-ray of implanted stent(s) 
▪ Venous Ulcer Assessment 
▪ CEAP Classification 
▪ Villalta Score 
▪ VCSS Pain Score 
▪ VEINES-QOL/Sym Questionnaire  
▪ EQ-5D-3L Questionnaire  
▪ Adverse event assessment 
▪ Review of concomitant medications 
▪ Follow-up venogram and IVUS may be required if DUS suggests >50% stenosis or occlusi on 
of the stented segment, and if the subject is symptomatic requiring a reintervention. If a 
follow-up venogram and/or IVUS is refused by the subject, this must be documented and 
will not be considered a protocol deviation and the DUS will be used if available.  
 
There is no follow-up or observation planned after the subject completes the 36-month fol low-up visit 
and is exited from the study.  
 
15.6. Unscheduled Visit  
An Unscheduled visit will be documented when a subject presents to the hospital or clinic between  
study-required follow-up visits and is seen by study personnel for a limb-relate d event, including 
reinterventions. The assessments below should be performed prior to any interve ntional procedures 
to the target limb. In addition, all imaging studies performed should follow the guid elines set forth 
by the respective core laboratory. This imaging should be submitted to the respective core 
laboratories within 3 business days for review and analysis.  
▪ SARS-CoV-2 Testing (if required per Section 9.2) 
▪ Venous Ulcer Assessment (if applicable) 
▪ CEAP Classification 
▪ Villalta Score 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 50 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
▪ VCSS Pain Score 
▪ VEINES-QOL/SYM Questionnaire  
▪ EQ-5D-3L Questionnaire  
▪ DUS (as clinically indicated) 
▪ Venogram and/or IVUS (as clinically indicated) 
▪ X-ray assessment (as clinically indicated) 
▪ Adverse event assessment 
▪ Review of concomitant medications  
Note:  Any change in concomitant medications, including any loading dose provided 
during an unscheduled procedure, should be recorded in the eCRF. 
 
15.7. Follow-up Visit Compliance 
As part of the informed consent process, all reasonable efforts will be made to obtain compl ete data 
for all subjects according to the follow-up visit schedule. PI and research staff will  be expected to 
maintain continuous and open communication with study subjects regarding their participati on in 
this study. 
Three attempts via telephone will be made to contact subjects who do not return for a stud y follow-
up visit. If after three telephone attempts the subjects cannot be contacted, a certified letter should 
be sent by the PI or designated study coordinator to the subject9s last known address.  If possible, 
public records should be searched to ascertain survival status.  If efforts to reach the subject are 
unsuccessful after three telephone contacts and a certified letter, and there is no evidence of 
subject expiration, or the site has not been notified of a subject9s wish to withdraw consent , a 
protocol deviation for a visit not done must be documented in the subject9s source records and 
reported in the EDC system. A detailed record of all contact attempts should be maintained in the 
subject9s file. This process should be repeated for all subsequently missed follow-up visits and 
documented accordingly. After required contact attempts are unsuccessful for at least 2 consecutive 
missed follow-up visits and the 12-month visit window (or any later subsequent visit wi ndow) has 
passed, only then should a subject be considered lost-to-follow-up (LTFU) and exited  from the study. 
In the event of a public health crisis, a global pandemic, a natural disaster, or any other event wh ich 
would preclude research sites from conducting research or restrict subject s9 ability to attend follow -
up visits, guidance will be provided by the Sponsor and may include performing  follow-up visits via 
alternative methods, extending visit windows, etc. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 51 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 
15.8. Subject Discontinuation and Replacement 
A subject may discontinue participation at any time without penalty or loss of benefi ts to which the 
subject is otherwise entitled. In addition, a subject may be discontinued if in the PI 9s opinion it is in 
the subject9s best interest . If a subject prematurely discontinues from the study, the reason will be 
recorded in the eCRF with supporting documentation.  These results will be tabulated by number 
and percent for each category for discontinuation.   
Subjects who prematurely exit the study after treatment will have their data maintained and 
evaluated up until the time of withdrawal. Subjects who are voluntarily or involuntaril y (per PI 
discretion or if LTFU) withdrawn cannot re-enter the study. These subjects will not be replaced. 
There is no follow-up or observation planned for subjects who withdraw voluntarily or w ho are 
involuntarily withdrawn by the PI.  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 52 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 RISK/BENEFIT ASSESSMENT  
16.1. Risks 
The use of the DUO Venous Stent System in treating venous obstructions may result in an ticipated 
potential risks or complications similar to other available endovascular implant devices (such as 
stents) used in these procedures. Such risks are included in the DUO Venous Stent System IFU and 
are listed below: 
▪ Access failure or abrupt closure 
▪ Allergic/anaphylactoid reaction to anticoagulant and/or antithrombotic therapy or contrast 
medium 
▪ Allergic reaction to Nitinol 
▪ Amputation 
▪ Aneurysm 
▪ Angina/coronary ischemia/myocardial infarction 
▪ Arrhythmia 
▪ Arteriovenous fistula 
▪ Death 
▪ Embolism 
▪ Emergent repeat hospital intervention 
▪ Extravasation 
▪ Fever 
▪ Gastrointestinal bleed from anticoagulation/antiplatelet medication 
▪ Hematoma/hemorrhage 
▪ Hypotension/hypertension 
▪ Incorrect positioning of the stent requiring further stenting or surgery 
▪ Intimal Injury/dissection 
▪ Ischemia/infarction or tissue/organ 
▪ Infection/abscess at insertion site 
▪ Inflammation  
▪ Malposition of stent 
▪ Multi-organ failure 
▪ Open surgical repair 
▪ Pain 
▪ Pulmonary Embolism  
▪ Pseudoaneurysm 
▪ Renal insufficiency or failure 
▪ Respiratory distress or failure 
▪ Restenosis 
▪ Rupture 
▪ Septicemia/bacteremia (sepsis) 
▪ Stent implant fracture 
▪ Stent implant migration (device moves over time) 
▪ Trauma to adjacent structures 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 53 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
▪ Vasospasm 
▪ Venous occlusion/thrombosis, remote from puncture site 
▪ Venous occlusion/thrombosis, near puncture site 
▪ Venous occlusion/restenosis of the treated vessel 
These risks are present in any endovascular treatment procedure for which the study subjects would 
be indicated because of their disease and will be reviewed with all subjects during the inform ed 
consent process. 
16.2. Potential Benefits 
• The DUO Stent may help improve the blood flow in the leg vein. 
• Participation in this study may yield information that is necessary for the develop ment of 
better or new treatments for this disease and may benefit other people who h ave the same 
blockages in the leg veins.   
16.3. Justification for Clinical Trial 
The safety of the DUO Venous Stent System  has been established through extensive design 
verification testing, including animal testing, and through a detailed risk analysis p rocess per ISO 
14971. The results of non-clinical testing have demonstrated safety and therefore it is anti cipated 
that the assessment of risk and benefit is appropriate for the intended use of the study device and 
the initiation of this study. 
This study is being conducted in to collect safety and efficacy data on the DUO Venous Sten t System 
to support an FDA Premarket Approval application. All efforts will be made to minim ize the 
occurrence of risk to study subjects through PI/institution qualification, PI trainin g on the safe and 
proper use of the device in accordance with the IFU, PI/site training on the protocol , and clearly 
defining subject eligibility requirements (inclusion/exclusion criteria) and con traindications as 
described in the IFU. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 54 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 SAFETY EVENTS AND REPORTING REQUIREMENTS  
The PI at each participating site is ultimately responsible for the timely review and reporting of AE s per 
respective IRB/EC policy and in accordance with FDA and ISO 14155 (OUS sites) requirements.  
The safety reporting period will begin at the time of enrollment into the study (See Section 13.3.1 for 
details on what constitutes subject enrollment) and will continue through study c ompletion.  
All protocol reportable AEs will be monitored from the time of enrollment through th e follow-up period 
for this study. A description of the event, including the start date, resolution (or date of final outcome 
assessment) date, action taken, and the outcome should be provided, along with the PI 9s assessment of 
the relationship between the event and the study device or study device procedure. Pain, neurological 
status, and functional impairment should be considered AEs when a subject9s complaint of any of these 
symptoms is outside the normal pattern for the illness treated. 
All protocol-reportable events reported during the safety observation period described above  should be 
followed until the event is resolved or judged to be chronically stable. Follow-up informati on will be 
submitted to the Medical Monitor and/or the Sponsor as it becomes available. 
In the event that the subject undergoes a SARS-CoV-2 test within 8 days of the index pro cedure and 
there is a delay in obtaining test results the subject may still be enrolled if they meet all of the other 
SARS-CoV-2 inclusion criteria, including successful completion of a COVID-19 quest ionnaire. If, when test 
results are received, the test result is positive, this must be recorded as an adverse event. This is the 
only adverse event that will be captured prior to enrollment, as the start da te of the adverse event 
will be the date of the SARS-CoV-2 testing, which occurred before the subj ect was enrolled.  
The Sponsor or its designee will include relevant adverse event information in annual Investigational 
Device Exemption (IDE) progress reports. Additionally, the Sponsor or its design ee will report all 
applicable serious adverse events as vigilance reports per MEDDEV 2.12.1, Rev 8 (2013) "Guideli nes on a 
Medical Devices Vigilance System= and as clinical trial reportable events per MEDDEV 2.7/3 <Clinical 
Investigations: Serious Adverse Event Reportin g=.  The Sponsor will determine whether all the local PIs 
need to be informed immediately of a serious adverse event (SAE) or unanticipated adverse device 
effect (UADE), or whether this can be postponed until the next regularly scheduled study update. 
 
17.1. Adverse Events  
An AE is any untoward medical occurrence, unintended disease or injury, or untoward clinical signs 
(including abnormal laboratory findings) in subjects whether or not related to the in vestigational 
device/procedure. 
If a pre-existing condition is present at enrollment, it must be recorded as an adverse event only if 
the frequency, intensity, or the character of the condition worsens during the study.  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 55 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
For the purposes of this study, all AEs, regardless of relatedness to the study device and/or study  
device procedure, target limb, or underlying venous disease are required  to be reported on the AE 
eCRF and are considered <protocol -reportable=.  
All protocol-reportable AEs will be evaluated by the PI using his/her clinical judg ement to determine 
whether the event further meets the criteria for adverse device effect (ADE), serious adverse event 
(SAE), serious adverse device effect (SADE), or unanticipated adverse device effect (UADE) and will 
be subject to the respective reporting requirements as outlined in the sections below. T he PI or 
designee is also responsible for informing their IRB/EC of adverse events as required by thei r IRB/EC 
reporting requirements and in conformance with FDA and local regulatory reporting requirements. 
In addition, the PI shall provide documentation of the report submitted to the IRB/EC to Vesper 
Medical or its designee. 
The following types of adverse events must be recorded on the AE eCRF by the PI (or de signee):   
▪ Serious Adverse Events 
▪ Any adverse event, regardless of relatedness to the study device, study device procedure, 
target limb, or underlying venous disease.   
 
The report will include: the AE term, seriousness, severity, action taken, treatment outcome, 
relationship of the adverse event to the study device and/or study device procedure, and the event 
status. 
All events will be made accessible to the Sponsor and/or designee to review the need for FD A 
regulatory reporting.  
Severity of adverse events will be classified according to the following criteria: 
Mild:  A mild adverse event is an AE usually transient in nature and generally not interfering with 
normal activities and not requiring intervention or treatment 
Moderate:  A moderate adverse event is an AE that is sufficiently discomforting to interfere with 
normal activities and may require intervention or treatment. 
Severe:  A severe adverse event is an AE that results in significant symptoms that prevent normal 
activities and may require hospitalization or invasive intervention.  
The relationship of the AE to the device or study device procedure will be classified accord ing to the 
following criteria: 
Unrelated:  The AE is clearly not related to the study device or study device procedure. 
Possibly:  Signs or symptoms of the AE may be related to the study device or study device 
procedure and/or the natural disease process or other injury/illness. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 56 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
Definitely:  The AE is clearly related to the study device or study device procedure. Signs and 
symptoms could not reasonably be related to the natural disease process or other inj ury or 
illness. 
Unknown:  Unable to determine the relationship between the study device, study device 
procedure, natural disease process and/or other injury/illness. 
In addition, all AEs will be assessed and recorded in the eCRF by the PI or Sub-I for relatedness to 
COVID-19 by indicating: 
• Yes, related to COVID-19 
• No, not related to COVID-19 
• Unknown 
17.2. Adverse Device Effects  
An ADE is defined as any untoward adverse event related to the use of an investigational device o r 
unintended response to a medical device.  
Note 1: This definition includes adverse events resulting from insufficient or inadequate Instruction s 
for Use, deployment, implantation, installation, operation, or any malfunction of t he investigational 
medical device(See Section 18 ). 
Note 2: This definition includes any event resulting from user error or from intentional m isuse of the 
investigational medical device (See Section 18 ). 
A list of events that may be associated with the study device and/or the study device procedure is 
provided in Section 16.1 .  
17.2.1.  ADE Reporting 
All ADEs must be evaluated to determine whether the event further meets criteria for a SADE 
(See Section 17.5.1 ) and would be subject to respective reporting requirements. Non-serious, 
anticipated ADEs must be reported by the PI (or designee) to the Sponsor and must also be 
submitted to the IRB/EC per the applicable reporting guidelines. If the event occurred as a result 
of a device event, respective reporting requirements must be followed as outlined in Section 18 .  
17.3. Serious Adverse Events  
A SAE is defined as an adverse event that:   
▪ led to death,  
▪ led to a serious deterioration in the health of the subject, that either resulted in: 
o a life-threatening illness or injury, or 
o resulted in a permanent impairment of a body structure or a body function, or 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 57 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
o required in-patient hospitalization or prolongation of existing hospitalization, or 
o resulted in medical or surgical intervention to prevent life-threatening illness or 
injury or permanent impairment to body structure or a body function, or,  
o led to fetal distress, fetal death or a congenital abnormality or birth defect.  
Note: Planned hospitalization for a pre-existing condition, or a procedure required by the 
investigational plan without serious deterioration in health, is not considered a serious adverse 
event.   
For study sites in Germany the following definition of a SAE according to article 3 MPSV (Ordi nance 
on the Medical Device Safety Plan) shall be considered: 
A serious adverse event is defined as <any untoward event that occurs during a clinical trial or 
performance evaluation requiring approval, which has led, could have led or might possibl y lead, 
directly or indirectly, to the death or serious deterioration in the state of health of a subject, user or 
another person, whether or not the event is related to th e medical device= (MPSV § 2 paragraph 5).  
17.3.1.  SAE Reporting 
All SAEs must be evaluated to determine whether the event further meets criteria for a SADE 
(See Section 17.5.1 ) and would be subject to respective reporting requirements. All events that 
meet the criteria above for SAEs must be reported by the PI (or designee) to the Sponsor within 
2 business days (Monday through Friday) from first knowledge of  event  and must also be 
reported to the IRB/EC per the applicable reporting guidelines. 
In Germany, the investigator must report any SAE to the sponsor immediately according to  
MPSV § 3 paragraphs 4 through 6. 
Any SAE with a potentially causal relationship between the event and the investigational 
medical device or procedures performed as part of the clinical trial or other conditions of th e 
trial conduct will be reported to BfArM immediately. Such related/potentially related SAEs 
occurring in Germany will be reported via the BfArM SAE report form and on the MEDDEV 2.7.3 
table. For all other SAEs, the reports will be submitted quarterly on MEDDEV 2.7.3 table. 
SAEs with a causal relationship occurring in other countries will be reported via the MEDDEV 
2.7.3 table to BfArM immediately after gaining knowledge and in accordance with the national 
requirements in the corresponding countries. For all other SAEs, the MEDDEV 2.7.3 table will be 
submitted quarterly on MEDDEV 2.7.3. 
Further, a quarterly evaluation has to be provided to BfArM considering all SAEs occurred in the 
study. The BfArM template shall be used for this report. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 58 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 
17.4. Major Adverse Events 
For this study, the definition of a MAE includes the following events that comprise safety and 
observational endpoints that require adjudication by the CEC: 
• Device or procedure-related death 
• Device or procedure-related bleed at the target vessel and/or the target lesion or at the 
access site requiring surgical or endovascular intervention or blood transfusion of g2 units  
• Device or procedure-related venous injury occurring in the target vessel and/or the target 
lesion or at the access site requiring surgical or endovascular intervention  
• Major amputation of the target limb 
• Clinically significant pulmonary embolism, confirmed by CT angiography 
• Stent embolization outside of the target vessel 
• Presence of new thrombus within the stented segment  
17.4.1.  MAE Reporting 
A major adverse event must be reported by the PI (or designee) to the Sponsor within 2 
business days (Monday through Friday)  from first knowledge of event  and must also be 
reported to the IRB/EC per the applicable reporting guidelines. 
17.5. Serious Adverse Device Effects  
A SADE is defined as an ADE that results in any of the consequences characteristic of a SAE. 
17.5.1.  SADE Reporting 
All events that meet the criteria above for a SADE must be reported by the PI (or designee) to  
the Sponsor within 2 business days (Monday through Friday) from first knowledg e of event  
and must also be reported to the IRB/EC per the applicable reporting guidelines. If the event 
occurred as a result of a device event, respective device event reporting requirements must be 
followed as outlined in Section 18 . 
17.6. Unanticipated Adverse Device Effects  
A UADE is defined as any serious adverse effect on health or safety, or any life-threatening problem 
or death caused by, or associated with, a device, if that effect, problem, or death was not previously 
identified in nature, severity, or degree of incidence in the investigational plan or applicati on 
(including a supplementary plan or application), or any other unanticipated serious problem 
associated with a device that relates to the rights, safety, or welfare of subjects. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 59 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
17.6.1.  UADE Reporting 
Any event that is suspected of meeting UADE criteria should be reported in the same manner as 
a SAE or SADE and must be reported by the PI (or designee) to the Sponsor within 2 business 
days (Monday through Friday) from first knowledge of event  and must also be reported to the 
IRB/EC per the applicable reporting guidelines. All SAEs will be reviewed by the Spon sor (or 
designee) to determine if UADE criteria is met, and if so, the Sponsor or designee will 
immediately conduct an evaluation and report the results of the evaluation to FDA, all rev iewing 
IRBs/ECs, and participating PIs within 10 business days after the Sponsor first receives notice of 
the UADE. 
17.7. Pregnancies  
Female subjects of childbearing potential must use some form of contraception (abstinence is 
acceptable) throughout the duration of the study. Each pregnancy occurring while the subject is 
enrolled in the study should be reported to the study Sponsor upon learning of its occurrence. 
Thereafter, the pregnancy should be followed to determine its outcome. 
17.8. Protocol Deviations and Protocol Violations 
A protocol deviation occurs when, without significant consequence, the activities on a study diverge 
from the IRB-approved protocol. Any protocol-required test, assessment, or procedure that is not 
done or is done out of window is considered a protocol deviation. For example, a subject missing a 
protocol-required visit due to being away on vacation, or a DUS that is done out of wind ow, would 
both be considered protocol deviations. All protocol deviations must be documented in EDC and  
reported to the Sponsor by the PI or designee upon first knowledge of the dev iation. 
A protocol violation is a divergence from the IRB-approved protocol that may reduce the  quality or 
completeness of data, makes the ICF inaccurate, or impacts a subject9s safety, rights, or welfare. 
Examples of protocol violations include, but are not limited to, the following: 
• Inadequate or delinquent informed consent; 
• Enrolled subject(s) who did not meet Inclusion/Exclusion criteria; 
• Unreported SAEs, UADEs, SADEs; 
• Multiple visits missed or visits that took place outside permissible windows; 
• Materially inadequate record keeping; 
• Intentional deviations from the protocol, GCP, or regulations by study personnel; 
• Repeated noncompliance with study requirements; 
• Events that may affect the outcome (endpoints) of the study, OR; 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 60 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
• Any other act or occurrence identified by the study Sponsor as constituting a violation from 
the protocol 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 61 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 STUDY DEVICE EVENT REPORTING  
A Study Device Event refers to the performance of the study device and the occurrence of a deficiency 
or malfunction as defined in sub-sections below. Device events are to be reported on the Dev ice Event 
eCRF and submitted to the Sponsor within 2 business days (Monday through Friday) of first know ledge 
of occurrence.  Any AE suspected of resulting from a device event must be reported per the required 
timelines as outlined in Section 17 .  
18.1. Device Deficiency 
Device deficiency is defined as inadequacy of a medical device related to its identity, qual ity, 
durability, reliability, safety, or performance, such as malfunction, misuse or not ob serving the IFU, 
and inadequate labeling. 
18.2. Device Malfunction 
A malfunction is defined as a failure of a device to meet its performance specifications or otherwise  
to perform as intended. 
18.3. Device Returns 
In the event that a device is suspected of deficiency or malfunction, the PI should make every effort 
to return the device to the manufacturer, Vesper Medical. The PI or designee shall contact Vesper 
Medical for a return manufacturer authorization number and for additional instructions for the 
return of potentially biohazardous material. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 62 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 STATISTICAL METHODS AND CONSIDERATIONS  
19.1. Introduction 
Descriptive statistics for each variable will be calculated which will include the n umber of 
observations, mean, standard deviation, median, minimum and maximum for continuous variab les 
and will also include the number and percent of observations for categorical variabl es.    
When the mean is found not to be an appropriate measure of central tendency, alternative statistics 
will be considered (e.g. median).  When the distribution of a variable does not support the  use of 
parametric statistics, nonparametric approaches or data transformations may be implemented.  If 
data transformations are used, they will be specified in the final clinical report.  
19.2. Analysis Groups 
A subject is defined as ITT and officially enrolled in the study once the DUO Venous Stent Syste m is 
advanced through the introducer sheath.   
Subjects in whom no DUO Stent implant is placed will be exited after 30 day s. Subjects in whom at 
least one DUO Stent implant is placed will be followed for 36 months.  
The full analysis set (FAS) are subjects who meet the ITT definition and have data evaluable for t he 
primary endpoints.  
The PP population will be defined as ITT subjects with evaluable data that have met the definitio n 
for device success, excluding subjects meeting criteria for a protocol violation(s) as o utlined in 
Section 17.8  and as determined by the Sponsor. 
In addition, a SARS-CoV-2 positive population will be defined as: 
1. Any documented confirmation of a SARS-CoV-2 positive test result 
or SARS-CoV-2 positive antibody test (at any approved testing site) 
from screening through study exit. Subjects will be grouped 
according to when they became SARS-CoV-2 positive based on the 
date that testing was performed as compared to the index 
procedure (i.e., within 30 days, greater than 30 days but within 12 
months, greater than 12 months). 
2. In the absence of a SARS-CoV-2 test, subjects will be required to 
complete a COVID-19 questionnaire. Any subject that completes a 
questionnaire after screening and answers YES to any question on 
the questionnaire will be included in the SARS-CoV-2 positive 
population. 
3. Regardless of SARS-CoV-2 status or COVID-19 questionnaire results, 
all adverse events will be assessed by the PI for relatedness to a 
possible COVID-19 infection by indicating YES, NO, or UNKNOWN. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 63 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
Any subject that has an adverse event where the PI indicates YES for 
relatedness will be included in the SARS-CoV-2 positive group. 
Due to the unknown but possible risks associated with COVID-19 and hypercoagulability, once a 
subject is placed in the SARS-CoV-2 positive population, they will remain there re gardless of future 
SARS-CoV-2 test results and or vaccination status. Any subject not meeting the abo ve criteria will be 
placed in the SARS-CoV-2 Negative population. 
19.3. Enrollment Sample Size 
The maximum sample size for primary safety and efficacy is that of primary safety or 140 subjects 
required at 30 days.   Conservatively, correcting that number for approximately 12.5% attri tion at 30 
days requires enrollment of 160 subjects.   With 160 subjects enrolled and accountin g for 20% 
attrition by 1 year, it is expected that 128 subjects will be evaluable for primary efficacy at 1 y ear 
providing 96 to 99% power depending on the proportion enrolled in each disease  state.   
19.4.  Study Success 
The study will be considered a success if the primary safety endpoint is met in either the SARS-CoV -2 
negative subset or all subjects and the primary efficacy endpoint is met in either the SARS-CoV -2 
negative subset or all subjects.  The Type I error for testing in both the SARS-CoV-2 negative subset 
and all subjects will be controlled using the Hochberg correction.    
19.5. Administrative Reports and Interim Reports 
An administrative report will be completed upon completion of enrollment to fix the perfo rmance 
goal for primary efficacy.  The study will enroll subjects from each of three disease states, i.e. 
nonthrombotic, acute thrombotic, and chronic postthrombotic.  The study will req uire that at least 
20% of the subjects are enrolled in each of the disease states.  The PG for the primary e fficacy 
objectives depends on the proportion of ITT subjects in each disease state.   Once enrollment is 
completed, the proportion of ITT subjects with nonthrombotic, acute thrombotic, and chronic 
postthrombotic disease will be calculated. The proportions are the weights in the formul a to 
calculate the PG.  The calculation is described in Section 19.11 , <Primary Efficacy Objective= . The PG 
for primary efficacy will be fixed in advance of or prospectively to the efficacy analyses. There is no 
Type I error adjustment for this report given that no hypotheses will be tested.   
The study data may be summarized prior to the time at which all N=160 enrolled subjects complete 
12 months of follow-up or exit the study early to fulfill an EU MDD post-market approv al 
requirement for CE Mark.  Since the interim look at the data set will not be used to claim early trial 
success with the FDA or to modify the study design, no correction to Type I error is required.   
Because of the potential to introduce bias into the study given knowledge of the interim results, 
Vesper Medical will create a standard operating procedure outlining the measures that will be taken 
to mitigate the risk of bias.   Main measures will include: identifying the roles wi thin the company 
who have visibility to the data, the security measures in place for storing the data,  com mitment 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 64 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
that no data will be shared with investigational sites until the full cohort is analyzed at 12 months 
and that the interim results will not be shared publicly via podium or publication.   
19.6. Pooling Evaluation 
The investigational sites will be tested for differences in the primary safety endpoi nt and primary 
efficacy endpoint in the FAS subset using Fisher9s Exact test  for both the SARS-CoV-2 negative subset 
and all subjects.   Subjects will be stratified by disease state to evaluate pooli ng for primary efficacy 
and not stratified for primary safety.  The Fisher9s Exact test will be performed 4 times,  once for each 
disease state for primary efficacy and once for primary safety.    
Investigational sites with less than 10 subjects per disease state will be comb ined for the purpose of 
the pooling evaluation with respect to the primary efficacy endpoint. In chrono logical order of site 
participation, sites with less than 10 subjects per disease state will be aggregated u ntil the pseudo-
site reaches >10 subjects per disease state. Once that happens a second pseudo-site will be created, 
etc. If the final pseudo-site is less than 10 subjects per disease state it will be comb ined with the 
previous pseudo-site.  Additionally, the poolability analysis will be con ducted with ONLY sites with 10 
or more subjects in each disease etiology.    
Investigational sites with less than 10 subjects overall will be combined for the purpose of the pooling 
evaluation with respect to the primary safety endpoint.  In order of site participation, sites with less 
than 10 subjects will be aggregated until the pseudo-site reaches >10 subjects.  Once that happens a 
second pseudo-site will be created, etc.  If the final pseudo-site is less than 10 subjec ts it will be 
combined with the previous pseudo-site. Additionally, the poolability analysis will be conducted with 
ONLY sites with 10 or more subjects.   
If there are any investigational site effects (i.e., statistically significant results at two- sided p <.15), a 
random center effect will be included in a logistic regression model to assess t he primary objective.  
If there are no differences, the data from all investigational sites will be pooled for the analyses.   
Additionally, the primary safety and efficacy endpoints will be summarized by US and OUS centers.  
The study was not powered to demonstrate the primary efficacy and safety endpoints within the 
subgroups defined by geography and therefore it is not an expectation that the primary safety and 
efficacy endpoint will be statistically significant within the subgroups determined by geograp hy. 
19.7. Handling of Missing Data 
A sensitivity analysis to the missing data in the ITT sample will be conducted for bo th the primary 
safety and efficacy endpoints in the SARS-CoV-2 negative subset and all subjects.  The sensitiv ity 
analysis will include a best case, worst case and tipping point analysis.  The best-case analy sis will 
impute successes for the missing data.  The worst-case analysis will impute failures for missing da ta.  
The tipping point analysis starts with the best-case analysis and continues until the worst-case 
analysis is completed, by increasing the number of missing cases imputed as failures by o ne in each 
analysis.   The goal of the tipping point analysis is to determine at what point the imputat ion of 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 65 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
failures causes the statistical evaluation of the endpoint to lose statistical significance.  If t he worst-
case analysis maintains statistical significance, the tipping point analysis is not necessary. 
 
19.8. Summary of Baseline Demographics, Index Procedure Measurements, and 
Subject Compliance  
Baseline demographics including at a minimum gender, age, and selected medical history w ill be 
summarized for ITT subjects overall and in the SARS-CoV-2 – negative subset for primary safety and 
for primary efficacy. In addition, angiographic characteristics and measurements, as well as 
procedure characteristics will be summarized.  
Subject follow-up and compliance with the protocol will be reported.  The number and percent of  
subjects enrolled, completing study-required follow-ups, and completing th e study will be 
summarized.  The subjects who exit the study early will be summarized along with the reason for 
early study termination. 
19.9. COVID-19 Statistical Considerations 
Given that COVID-19 has been associated with a hypercoagulable state which has the potential to 
increase MAE occurrence and decrease patency, the study has been modified to test the primary 
safety and effectiveness hypotheses in both the SARS-CoV-2 negative subset and all subjects 
(regardless of SARS-CoV-2 status).    
The performance goals for both primary safety and primary effectiveness were established based on 
research in a pre-COVID-19 era and therefore do not account for potential increases in MAEs o r 
decreases in patency associated with SARS-CoV-2 or COVID-19.   For each of the hypothesis tests, 
the current plan is to use the same performance goal in all subjects and in the SARS-CoV-2  negative 
subgroup given that the potential effects due to SARS-CoV-2 are not well understood.  Th is decision 
will be revisited prior to analysis of the study data. In the event that additional information becom es 
publicly available regarding SARS-CoV-2, as related to the VIVID study primary endp oints, we may 
summarize the major event rate and primary patency in the subject population without an d with 
SARS-CoV-2, and if possible, further based on the extent of COVID-19 illness.  Should this 
information suggest that it may be reasonable to lower the performance goal for the all sub ject 
cohort, negotiation with FDA will be pursued given the FDA guidance document, <Statistical 
Considerations for Clinical Trials During the COVID- 19 Public Health Emergency= dat ed June 2020.       
19.10.  Primary Safety Objective 
Subjects Included the Analysis:  Subjects who meet the ITT definition.   
Endpoint:  The primary safety endpoint is freedom from major adverse events (MAEs) at 30 days post 
index procedure evaluated per subject. MAEs are defined in Section 6.1  Primary Endpoints. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 66 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
Performance Goal:    Disease state specific PGs were calculated from the point estimates for major 
bleeding, pulmonary embolism and peri-procedural mortality from Razavi et al1 converted to 
freedom from estimates and application of a 10% non-inferiority margin.   For example, the 
expected freedom from the combined primary safety event for nonthrombotic subjects is 100  – (0.3 
+ 0.2 + 0.1) = 99.4%.   Therefore, the PG for the nonthrombotic group is 99 – 10 = 89%.   The same 
calculation for the acute-thrombotic group results in an 87% PG, 87%=100 – (1.1 + 0.9 + 0.7) – 10.   
Lastly, the PG for chronic postthrombotic is 88%=100 – (0.9 + 0.6 + 0.3) – 10.  Given the similarity of 
the disease-state specific PGs, it was determined that a disease state specific goal was not 
necessary.  A PG of 89% was adopted for the study in both the SARS-CoV-2 negative subset and 
overall.   
  Hypothesis and Performance Goal :   
H0:  Proportion of subjects with freedom from MAE (p MAE) is less than or equal to the (PG) at 30 days, 
pMAE  f89% 
H1:  Proportion of subjects with freedom from MAE is greater than the (PG) at 30 days, p MAE >89% 
The freedom from MAE proportion will be calculated such that the numerator is the number of 
subjects in whom a MAE did not occur within 30 days of the index procedure.  The denominato r is 
the number of subjects with 30 days of follow-up plus the number of subjects with a MAE prior to 30 
days who exited the study prior to 30 days, if any. 
Sample Size Rationale :  Using PASS 19, a one-sample Exact Test (binomial enumeration), power = 
90%, one-sided Type I error controlled at 2.5%, and assumed freedom from MAE of 96.1% with a PG 
goal of 89%, the required evaluable sample size is 140 subjects. 
Primary Statistical Analysis : The primary statistical analysis will be conducted in the FAS subset for 
the primary safety endpoint overall and in the SARS-CoV-2 negative subset.  The primary statistical  
method is a one-sample exact test comparing the proportion of subjects free from a MAE to the PG 
using a two- sided α= 0.0 5. The exact two-sided 95% confidence interval for the proportion of 
subjects free from MAE will be calculated.    
The two-sided p-value in the SARS-CoV-2 negative subgroup and all subjects will be calculated and 
ordered from largest to smallest.   If the largest p-value, is statistically significant at p < 0.05 t hen the 
hypothesis test is statistically significant in both the SARS-CoV-2 negative subset and all sub jects.   If 
not, testing continues to the smallest p-value.   If the smallest p-value < 0.025  then the hypothesis 
test is statistically significant in the group for which the smallest p-value is asso ciated with.   If the 
 
1 Razavi MK, Jaff MR, Miller LE.  Safety and Effectiveness of Stent Placement for Iliofem omral Venous Outflow 
Obstruction Systematic Review and Meta-Analysis.  Circ Cardiovasc Interv. 2015;8:e002772.  DOI:  
10:1161/CIRCINTERVENTIONS.115.002772.) 
 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 67 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
smallest p- value g 0.025, t hen the hypothesis test is not statistically significant in either the SARS-
CoV-2 negative subset nor all subjects.   
Additional Analysis :  The evaluation for pooling analyses specified in  Section 19.6  will be completed.  
If there is missing data for the ITT subjects, the sensitivity to missing data analysis outlined in 
Section 19.7  will be completed.  Additionally, the primary statistical analysis will be conducted i n the 
per protocol sample overall and in the SARS-CoV-2 negative subset.   
19.11.  Primary Efficacy Objective 
Subjects Included the Analysis:  Subjects who meet the ITT definition. 
Efficacy :  Primary patency of stented segment (confirmed by core laboratory) at 12 months 
evaluated per subject.  
Hypothesis :  
H0:  Proportion of subjects with primary patency (p p_pat) is less than or equal to performance goal 
(PG) at 12 months, p p_pat fPG 
H1:  Proportion of subjects with primary patency is greater than the performance goal at 12  months, 
pp_pat >PG 
The primary patency proportion will be calculated such that the numerator is the number of 
subjects found to be patent at 12 months. The denominator is the total number of subjects fo und to 
be patent or not patent at 12 months. 
Patency is: 
• An in-window patent stenosis assessment with no reintervention per definition prior to the 
close of the 12-month window.    
• In the absence of an in-window stenosis assessment, a subsequent patent stenosis 
assessment with no prior reintervention per definition can be used to declare patency at 12 
months.   
 
Lack of patency is: 
• A reintervention per definition prior to the close of the 12-month visit window.  
• A non-patent stenosis assessment within the 12-month visit window.   
 
Performance Goal :   The PG for primary efficacy will be set when all enrolled subjects complete the 
index procedure of this pivotal IDE trial based upon the proportions of ITT subjects in each of the 
disease states, i.e. nonthrombotic (p NT_ENROLL ), acute thrombotic (p AT_ENROLL )   and chronic 
postthrombotic (p CPT_ENROLL ).   The disease state specific PGs were adopted as suggested in Razavi et 
al1 that is, the lower 95% confidence limit minus 0.10.   The disease state PGs are .83,  .70 and .66 for 
nonthrombotic, acute thrombotic and chronic postthrombotic subjects respectively.  The PG for the 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 68 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
pivotal study will be a weighted combination of these disease state specific PGs, where the weights 
are the proportion of subjects in each disease state in the ITT sample, i.e. study PG =(p NT_ENROLL )*0.83 
+ (p AT_ENROLL )*.70 +  (p CPT_ENROLL )*0.66.   The same PG will be used overall and in the SARS-CoV-2 
negative subgroup. In order to have a minimum number of subjects from each disease conditio n in 
the ITT sample, the study will require that at least 20% of the ITT subjects are in each of the disease 
state.    
Sample Size Rationale :  With an expected FAS sample size of N=128, one-sided Type I error less than 
or equal to 2.5%, and assumed primary patency at 12 months equal to .96, .87, .79, i.e. the poi nt 
estimates for primary patency from Razavi et al for nonthrombotic, acute thrombotic, and chron ic 
postthrombotic respectively, the power for primary efficacy ranges from 96 – 99% depending on 
proportion in each disease-state given a minimum of at least 20% in each group.  The table below 
provides the matrix of simulated power varying the ITT proportions for the disease states.  
Power Calculations Using Simulation for the Primary Statistical Anal ysis 
Proportion of Subjects 
Expected in Each Group  Assumed Freedom from  
Primary Efficacy Calculated Performance Goal Power at 
N=128 
Evaluable 
(20% 
attrition 
for N=160 
enrolled  
NT AT CPT NT AT CPT Pooled NT AT CPT  PG One-sided 
Type I 
error = 
2.5%  
0.3333 0.3333 0.3333 0.96 0.87 0.79 0.873 0.83 0.7 0.66 0.73 98% 
0.2 0.2 0.6 0.96 0.87 0.79 0.84 0.83 0.7 0.66 0.702 96% 
0.2 0.6 0.2 0.96 0.87 0.79 0.872 0.83 0.7 0.66 0.718 99% 
0.6 0.2 0.2 0.96 0.87 0.79 0.908 0.83 0.7 0.66 0.77 96% 
0.3 0.3 0.4 0.96 0.87 0.79 0.865 0.83 0.7 0.66 0.723 97% 
0.3 0.4 0.3 0.96 0.87 0.79 0.873 0.83 0.7 0.66 0.727 99% 
0.4 0.3 0.3 0.96 0.87 0.79 0.882 0.83 0.7 0.66 0.74 98% 
0.4 0.4 0.2 0.96 0.87 0.79 0.89 0.83 0.7 0.66 0.744 99% 
0.4 0.2 0.4 0.96 0.87 0.79 0.874 0.83 0.7 0.66 0.736 98% 
0.2 0.4 0.4 0.96 0.87 0.79 0.856 0.83 0.7 0.66 0.71 98% 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 69 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 
Primary Statistical Analysis : The primary statistical analysis will be conducted in the FAS subjects 
overall and in the SARS-CoV-2 negative subgroup.   The primary statistical comparison wil l use a one-
sample Z-test comparing the proportion of subjects with primary patency to the PG using a one-
sided α= 0.025 equivalent to a z -score of 1.96.  The variation in the proportion will be estimated 
using the disease-specific performance goals themselves, i.e. under the null, rather than use the 
estimated patency rates, i.e. under the alternative.  
The estimates that will be observed for primary patency in each disease etiology are noted as 
follows: 
p̂p_pat_NT = The primary patency observed in the NT subjects. 
p̂p_pat_AT = The primary patency observed in the AT subjects. 
p̂p_pat_CPT = The primary patency observed in the CPT subjects.  
 
The percent of subjects in the FAS with each disease etiology are noted as follows: 
pNT_FAS =  The proportion of FAS subjects with NT disease etiology.   
pAT_FAS =  The proportion of FAS subjects with AT disease etiology.  
pCPT_FAS =  The proportion of FAS subjects with CPT disease etiology. 
 
The number of subjects in the FAS set with each disease etiology are noted as follows:  
nNT_FAS  = The number of FAS subjects with NT disease etiology.    
nAT_FAS  = The number of FAS subjects with AT disease etiology.    
nCPT_FAS  = The number of FAS subjects with CPT disease etiology.    
 
The primary patency for the hypothesis test is calculated as:  
pp_pat = p NT_FAS * p̂p_pat_NT + pAT_FAS * p̂p_pat_AT + pCPT_FAS * p̂p_pat_CPT 
with the variance of primary patency calculated as follows:  
var(pp_pat) = ((p NT_FAS)2 PG NT(1 - PG NT))/ n NT_FAS + ((p AT_FAS)2 PG AT(1 – PG AT))/ n AT_FAS + ((p CPT_FAS)2 PG CPT(1 – 
PG CPT))/ n CPT_FAS 
Such that the Z score is calculated as follows:  
Z =(p p_pat – PG)/square root( var(pp_pat))  
When Z >1.96, the primary patency is found to be significantly greater than the performance goal 
with two-sided Type I error held at 5%, i.e. two-sided p-value < 0.05.   
The two-sided p-value in the SARS-CoV-2 negative subgroup and all subjects will be calculated and 
ordered from largest to smallest.   If the largest p-value, is statistically significant at p < 0.0 5 then the 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 70 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
hypothesis test is statistically significant in both the SARS-CoV-2 negative subset and all subj ects.   If 
not, testing continues to the smallest p-value.   If the smallest p-value < 0.025  then the hypothesis 
test is statistically significant in the group for which the smallest p-value is asso ciated with.   If the 
smallest p- value g 0.025, then the hypothesis test is not statistically significant in either the SARS-
CoV-2 negative subset nor all subjects.   
 
Additional Analysis:   As a supportive analysis to the primary patency analysis, a Kaplan-Meier 
analysis will also be performed using the patency data overall and in the SARS-CoV-2 negative 
subset.    Time 0 is the index procedure and the event is lack of patency based on 1) reinterventio n 
per definition 2) a non-patent stenosis assessment within the 12 month visit window.   For sub jects 
who do not experience an event, the time of censoring is the date of the last follow-up wh ether 
scheduled or unscheduled.    
The evaluation for pooling analyses specified in Section 19.6  will be completed.  If there is missing 
data for the ITT subjects, the sensitivity to missing data analysis outlined in Section 19.7  will be 
completed.   Additionally, the primary statistical analysis will be conducted in the per protoco l 
sample overall and in the SARS-CoV-2 negative subset.   
19.12.  Subgroup Summaries for Primary Endpoints 
Summary statistics for the following subgroups will be summarized.  The study was not powered to  
demonstrate the primary efficacy and safety endpoints within the subgroups and therefore it is no t 
an expectation that the primary safety and efficacy endpoint will be statistically significant withi n 
the subgroups defined by disease etiologies (NT, AT, CPT), gender, age, race and ethnicity.  Age 
subgroups are defined by dichotomizing at the median.       
19.13.  Secondary and Observational Endpoints 
The secondary endpoints are listed in Section 6.2 and the observational endpoints are listed in 
Section 6.3 and are supportive in nature.  Descriptive statistics will be calculated and may be 
provided in labeling if deemed informative for the user.  Descriptive statistics for the purposes of 
labeling are defined as N, mean, standard deviation, median, interquartile range, minimum and 
maximum for continuous variables, and number and percent of observations for categorical  
variables.   
Standard statistical methods will be used and include the Kaplan-Meier product limit method for 
time to event endpoints and the Wilcoxon signed rank test for changes from baseline for endpoints 
compared to baseline.  Statistical significance will be defined as two-sided α <0.05.  Two-sided 95% 
confidence intervals may be calculated for estimates.  P-values and 95% confidence interval s are not 
intended for the labeling. 
Safety and efficacy endpoints will be evaluated in the sample of subjects meeting the ITT  and PP 
definition in both the SARS-CoV-2 negative subgroup and all subjects.   
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 71 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 REGULATORY AND ETHICAL OBLIGATIONS  
As the study Sponsor, Vesper Medical is responsible for the overall conduct and quality of the  study, 
including the assurance that the study complies with the regulations and guidance that apply to m edical 
devices evaluated under an IDE and GCP guidance (FDA Regulations, ISO 14155, and ICH E6). 
Additionally, Vesper Medical will ensure that qualified monitors and designated personnel are 
monitoring the study and that the Informed Consent process is followed per each site9s local and 
national requirements. 
20.1. Institutional Review Board / Ethics Committee Approval  
21 CFR Parts 50 & 56; ISO 14155  
The PI at each participating site is responsible for securing IRB/EC approval for this study proto col and 
the informed consent documents. The IRB/EC for each specific institution must review and appro ve this 
study protocol, the specific informed consent form, and any written materials for subjects to be used at 
that site prior to enrollment of the first subject.  The Sponsor must  also review and approve the final 
informed consent documents prior to their use.  The Sponsor must receive a copy of any IRB/EC  
correspondence as well as the final approval letter and the final approved informed consent form  from 
each IRB/EC. The IRB/EC approval letter must be signed by the IRB/EC chair or designee, identify th e 
IRB/EC name and address, the clinical trial protocol by name or number, and the date the approval  was 
granted. 
The PI is also responsible for initiating and obtaining continuing review of th e clinical trial. Continuing 
IRB/EC review and approval should not exceed intervals over one year but may occur at more frequent 
intervals as required by site specific IRB/EC policies. The PI must also provide the Sponsor w ith all 
correspondence and documentation of continued IRB/EC approval of the clinical trial. 
20.2. Informed Consent 
All sites shall comply with 21 CFR 50, provisions of ICH GCP, local IRB/EC policy, and all ap plicable local 
regulations (i.e. ISO 14155 for OUS Sites) for obtaining informed consent. Written info rmed consent is to 
be obtained for all subjects prior to treatment as described in Section 10.1 .  
Informed consent templates will be provided by the Sponsor to all participating clinical sites. Changes to 
this template made by the site based upon IRB/EC requirements must be provided to the Sponsor f or 
review and approval prior to being submitted to the IRB/EC for review and approval. Any rev isions 
required by a site9s IRB /EC should also be provided to the Sponsor for review and approval prior to being 
submitted to the IRB/EC for final review and approval.  
20.3. Protocol Amendment and Emergency Deviations 
Changes to the research conducted under this protocol will be implemented with a formal pr otocol 
amendment. Amendments to the protocol may be initiated by the Sponsor or at the request of an PI. In 
either case, changes to the protocol must be approved by the Sponsor and submitted to the applicab le 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 72 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
regulatory agency as appropriate. A protocol amendment cannot be implemented at the site without 
first being signed and acknowledged by the Investigator and approved by the IRB/EC. 
Emergency deviations or modifications may be initiated without prior Sponsor or IRB/EC  approval only 
in cases when the deviation is necessary to eliminate an immediate potential hazard to a subject. 
Emergency deviations or modifications implemented to protect the life or physical well-bein g of a 
subject must be reported to the Sponsor and site-specific IRB/EC within 5 business days of occurrence.    
20.4. Subject Confidentiality 
Confidentiality of subjects will be maintained throughout the study. A unique identifi cation code will be 
assigned to each subject enrolled into the study .  Access to the subject9s medical records will be limited 
to authorized personnel of the Sponsor, their designated monitors, clinical site study staff, and 
authorized regulatory authorities as required by the IRB/EC and/or local or national agencies. Any data 
that may be published in abstracts or scientific journals and/or presented at medical meetings wil l at 
most reference the unique subject code and will not reveal any subject9s identity.  The Sponsor and their 
representatives will make every reasonable effort to protect the confidentiality of the subj ects 
participating in the study. 
All U.S. clinical trial sites must comply with the provisions of the Health Insurance P ortability and 
Accountability Act (HIPAA) and in accordance with all applicable federal, local and institutional 
requirements. All European Union (EU) sites must comply with the provisions of the General D ata 
Protection Regulation (EU) 2016/679) and in accordance with all applicable federal, local and 
institutional requirements. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 73 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 CLINICAL TRIAL CONDUCT  
21.1. Principal Investigator and Site Qualification 
21 CFR 812.43; ISO 14155 
All PIs and investigational sites will be selected by Vesper Medical through the PI and site qualification 
process. All selected PIs will be responsible for complying with all study-related and regulator y 
requirements and will be ultimately responsible for overseeing the conduct of the study at th eir 
respective investigational sites, per the Investigator Agreement.  
All selected PIs will have the required training and expertise in performing peripheral vascular 
interventional procedures in a clinical research setting. The investigational sites where the stud y 
procedures and assessments are to be performed must have the adequate volume of the target sub ject 
population, experienced staff, as well as the appropriate facilities and equipment to meet the 
requirements of the study protocol and the expected enrollment time frames. 
All PIs and research staff must be willing to undergo all study and device-related training and parti cipate, 
assist, and comply with monitoring, audits, and inspections initiated by either the Sponsor  and/or 
regulatory authorities.  
21.2. Principal Investigator and Site Training 
Training of the PI and clinical trial staff is the responsibility of the Sponsor and/or their designee.  PIs and 
study staff will undergo site initiation visit training on the use of the study device, t he study protocol, 
eligibility criteria, and device accountability prior to participating in the study. Train ing will also include, 
but is not limited to, instructions on timely and accurate eCRF completion, safety repo rting timelines, as 
well as procedures for acquiring study-related images and associated timelines for submission to 
appropriate core laboratories. All training of the PIs and research staff must be docum ented on the site 
training log before performing any study-related function(s). 
21.3. Clinical Monitoring 
21 CFR 812.46; ISO 14155 
Vesper Medical will designate qualified clinical monitors and oversee the conduct of this stud y.  The 
clinical monitors will evaluate compliance with the protocol, GCP (FDA Guidance, ISO 1 4155, and ICH 
E6), any specific recommendations made by the site9s IRB /EC, and the signed Investigator and Study 
Agreements.   
The clinical monitor will conduct periodic monitoring visits to verify that the e CRFs agree with the source 
documentation and other records, that the rights and well-being of the subjects are being protec ted, 
and that the trial is being conducted in accordance with the approved protocol/amendments and GCPs. 
At the discretion of the Sponsor, periodic monitoring visits may occur either in-perso n or remotely. 
Periodic phone contact will also be conducted to ensure that the protocol is being followed  and to assist 
the site with queries or other issues that may arise.  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 74 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
For record verification purposes during site monitoring visits, the clinical monitor  and/or authorized 
Sponsor representative will be provided access to hospital records, original laboratory data, and other 
records and data as it relates to the study and as agreed to with the PI prior to the initiation of  the trial.  
The PI will also make available to the clinical monitor all regulatory docum ents, all completed eCRFs, 
informed consent documents, source documentation, and other relevant records for all enrolled 
subjects at the site.  It is important that the PI and other relevant site personnel are available f or 
consultation with the clinical monitors during the monitoring visits and that sufficient time is devoted at 
the site to the monitoring process.  
If the Sponsor and/or their authorized representative become aware that a PI is not complying wi th the 
study protocol, the PI Agreement, the Declaration of Helsinki, GCPs, applicable privacy standards, or an y 
condition of the study imposed by the IRB/EC, the Sponsor or their authorized representative may 
immediately secure compliance, discontinue further shipments of the study devices and/or seize u nused 
devices on-site.  An inability to secure compliance and/or to complete an investigation i nto the factors 
that are inhibiting compliance may result in the PIs termination from the study by the Spons or.   
Study close-out visits will be conducted after the final follow-up visit is com pleted at each site.  
Following the resolution of any outstanding data discrepancies and adverse events, the remainin g study 
devices will be the collected and returned to the Sponsor.  A final study report will be generated and 
submitted to the PI and the appropriate study oversight authorities.  Study document retention  
requirements will be reviewed with each site during the close-out visit. 
21.4. Device Accountability 
All study devices will be provided to the PI by the Sponsor after being tested, released, an d shipped 
according to appropriate standards. The PI and/or designee is responsible for the secure storag e of and 
controlled access to the study devices and accountability. The study device shall not be dispensed to  any 
person who is not a consented study subject under this protocol. 
21.5. Investigator Reports 
21CFR Parts 50 & 56; ISO 14155:2011 Section 4 
All PIs will be responsible for preparing and submitting the following complete, a ccurate, and timely 
reports:  
To the Sponsor and the IRB/EC:  
▪ Any unanticipated adverse device effect occurring during an investigation as soon as 
possible but no later than 2 business days after first learning of the effect.  
▪ Assist Sponsor in generating progress reports on the investigation at regular intervals, but i n 
no event less often than yearly. If there is a study monitor, a copy of the report will also be 
sent to the monitor.  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 75 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
▪ Any deviation from the investigational plan made to protect the life or physical well-b eing of 
a subject in an emergency, as soon as possible but no later than 5 working days after the 
emergency occurs. Except in emergency situations, a protocol deviation may require prior 
Sponsor approval. If the deviation may affect the scientific soundness of the plan or th e 
rights, safety, or welfare of subjects, prior FDA and IRB/EC approvals are required. 
▪ Any use of the device without obtaining informed consent must be reported within 5 
working days after such use.  
▪ Assist Sponsor in generating a final report within 3 months following termination or 
completion of the investigation or an individual PI 9s part of the investigation.  
▪ Any further information requested by FDA or the IRB/EC about any aspect of the 
investigation.  
To the Sponsor:  
▪ Withdrawal of IRB/EC approval of the PI 9s part of an investigation. (Due within 5 working 
days of such action). If the PI 9s IRB/EC withdraws their approval to conduct this study for any 
reason, the PI must notify the Sponsor as soon as possible, but no later than five workin g 
days after the withdrawal of the approval. 
In addition, the PI is responsible for the reporting of all safety and device events per th e timelines 
specified in Section 17  and Section 18 .  
 
21.6. Data Collection and Management 
Standardized eCRFs will be used to collect complete and accurate records of the clinical data requ ired by 
the study in accordance with GCP guidelines.  The PI and/or study staff under his/her directi on is 
responsible for accurately recording the clinical data for this study within five (5) busin ess days after 
each visit. 
Continuous review of the data will be performed by qualified data managers to ensure accuracy and 
consistency. Data review will persist until the data are clean and ready for approval and locking.  
 
21.7. Safety Monitoring 
21.7.1.  Data Safety Monitoring Board  
To meet the ethical responsibilities and standards for research subjects, an independent board of mul ti-
disciplinary physicians and subject matter experts shall serve as the Data Safety and Monitori ng Board 
(DSMB) for the study.  In order to enhance objectivity and reduce the potential for bias, t he DSMB shall 
be independent of the Sponsor as well as the investigational sites/ PIs.  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 76 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
The DSMB shall serve as an independent body conducting a review and oversight of all key safety events  
to monitor the rate of occurrence (both site reported and CEC adjudicated events) as part of thei r 
mission to protect the rights and safety of research subjects. The DSMB will define the types of ev ents 
that may require real-time reporting and the format and frequency of interim data reviews for 
aggregate event rates. The DSMB will conduct systematic interim safety reviews at pre-specified 
intervals as outlined in the DSMB charter.  The committee will be responsible for making an y 
recommendations to the Sponsor it deems necessary to protect subjects enrolled in the trial. 
At the close of each meeting, deliberation will occur and each DSMB member will vote  in favor of 
continuation of the study as designed, or modification of the study to protect the wel fare of subjects 
enrolled into the study. The result of this vote will be recorded in the meeting minutes.  
The methodology for performing these responsibilities shall be developed and outlined in the DSMB 
Charter.  
21.7.2.  Clinical Events Committee  
An independent CEC consisting of a team of clinical experts with experience in the conduct of cl inical 
trials shall be formed to review clinical events reported by the PIs, or at the request of the Spon sor to 
determine if they meet the pre-specified endpoint definitions. The CEC may also be called upo n to 
review relevant SAEs to assess the relationship to the study device and/or study procedure. The CEC9s 
determination of whether a clinical event meets the study-defined endpoint will be co nsidered the 
primary determination for the purpose of reporting study results with the exception of endp oints 
derived from core laboratory analysis. 
Operational provisions shall be established to minimize potential bias (i.e., the physicians s erving on the 
CEC shall be blinded to the clinical site to the extent possible during adverse event review and 
adjudication). The methodology for performing these responsibilities will be ou tlined in the CEC Charter. 
The CEC will define the minimum required information necessary to facilitate their review of an event. 
This may include information from original source documentation and imaging media. 
21.8. Medical Monitoring 
The Sponsor will be responsible for identifying a Medical Monitor who possesses the appropria te 
expertise and medical knowledge to oversee all adverse events reported during the study. All advers e 
event reports will be directed to the Sponsor as well as the Medical Monitor. The Medical Monitor wi ll 
be responsible for first-line and timely review of all adverse events in order to i dentify the seriousness, 
severity, causality, and expectedness (anticipated vs. unanticipated) of the event to the study  device 
and/or study procedure. The Medical Monitor will also have responsibilities including  but not limited to: 
▪ Reviewing all reported AEs for UADE potential and notifying the Sponsor of the need for 
regulatory reporting; 
▪ Determining the need for additional information or supporting documentation from  the site 
regarding an adverse event to facilitate complete assessment; 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 77 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
▪ Providing thorough review and assistance, as needed, for generating documents (i.e., 
subject event narratives) subject to CEC review and adjudication; 
▪ Providing answers to the sites, IRBs/ECs, and/or Sponsor to questions requ iring medical 
expertise that pertain to the protocol (i.e., subject eligibility) or any other medical aspect o f 
the study; 
▪ Identifying potential need for an amendment to the protocol; 
▪ Providing a review of safety information included in regulatory reporting, as needed. 
The Medical Monitor will review all adverse events throughout the duration of the study un til study 
completion. 
21.9. Central Core Laboratories 
To ensure that the clinical data and images are analyzed in a controlled, non-biased manner and that  the 
results are analyzed using a standardized process, all venograms, intravascular ultrasounds, duplex 
ultrasound studies and X-rays obtained during this study will be submitted to a respect ive central core 
laboratory for analysis. Any core laboratories used during the conduct of this study  will be identified and 
selected by the Sponsor.   
The core laboratories will be responsible for analyzing the venograms, intravascular ultraso unds, duplex 
ultrasounds, and X-ray images according to the study eligibility criteria, the s tudy endpoints, and 
requirement measurements according to the study protocol. Feedback will be provided to the  sites and 
Sponsor regarding the quality of the tracings and images.  
21.10.  Record Retention 
The PI is responsible for maintaining the following accurate, complete, and current records re lating to 
his/her participation in this investigational study:  
▪ Correspondence with another PI, an IRB/EC, the Sponsor, a monitor, or FDA; 
▪ Records of receipt, use, or disposition of a device that relate to:  
o The type and quantity of the device, dates of receipt, and batch numbers or code 
marks;  
o Names of all persons who received, used, or disposed of each device;  
o The number of units of the device returned to the Sponsor, repaired, or otherwise 
disposed of, and the reason(s) therefore. 
▪ Records of each subject 9s case history and exposure to the device, including:  
o Documents evidencing informed consent and, for any use of a device without 
informed consent, any written concurrence of a licensed physician and a brief 
description of the circumstances justifying the failure to obtain informed consent; 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 78 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
o All relevant observations, including records concerning adverse device effects 
(whether anticipated or not), information and data on the condition of each subject 
upon entering and during the course of the investigation, including informatio n 
about relevant previous medical history and the results of all diagnostic tests;  
o A record of the exposure of each subject to the investigational device, including the 
date and time of each use, and any other therapy;  
▪ The protocol, with documents showing the dates of and reasons for each deviation from the 
protocol; and  
▪ Any other records that FDA requires to be maintained by regulation or by specific 
requirement for a category of investigations or a particular investigation. 
In addition, all PIs and Sub-Is shall disclose to the Sponsor sufficient and accurate financial inf ormation 
to allow the Sponsor to submit certification or disclosure of financial interests under 21 CFR  54. All PI(s) 
and Sub-I(s) shall update the information if any relevant changes occur during the course of the 
investigation and for one year following completion of the study. 
The Sponsor, core laboratories, and clinical sites will maintain the study records u ntil two (2) years after 
the last marketing application and until there are no pending or contemplated marketing application s or 
at least two (2) years have elapsed since formal discontinuation of clinical development of the  
investigational product. These records may be retained for a longer period of time if requi red by 
applicable regulatory agencies or by the Sponsor.  In such an instance, it is the responsibility o f the 
Sponsor to inform the PI/institution as to when these documents no longer need to be retai ned. The 
Sponsor will notify each site regarding the regulatory requirements for record retention durin g the study 
close-out visit. 
Per regulations in Germany § 10 (7) MPKPV, the record retention period for the study docum ents shall 
be at least ten (10) years after the end of the study. These records may be retained for a longer p eriod 
of time if required by applicable regulatory agencies or by the Sponsor.  
21.11.  Audits/Inspections 
In accordance with GCP requirements, the Sponsor and/or designee may request access t o all study 
records, including source documents, for inspection and duplication at any time.  In the e vent that a PI is 
contacted by an applicable regulatory body in relation to this study, the PI will notify the Sponsor as 
soon as possible.   
The PI and/or designees must be available to respond to reasonable requests by the authoriz ed Sponsor, 
Clinical Research Organization (CRO) and regulatory agency representatives during the monitori ng and 
inspection process.  The PI must provide the Sponsor with copies of all correspondence that may aff ect 
the review of the current study (i.e. inspection observations) or their qualification as a P I in clinical 
studies conducted by the Sponsor. The Sponsor will provide any needed assistance to the c linical site for 
regulatory audits.   
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 79 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 
21.12.  Study Termination (Stopping Rules) 
The Sponsor, IRBs/ECs, or regulatory authorities may terminate the study if the safety and well-bein g of 
study subjects is in jeopardy. If the PI terminates the study at his/her site without prior appr oval by the 
Sponsor, all details must be provided promptly to the Sponsor and IRB/EC. 
The Sponsor reserves the right to terminate or reevaluate a site for continued participati on in the study 
at any time for any of the following reasons: 
▪ Unsatisfactory enrollment with respect to eligibility criteria 
▪ Failure to obtain Informed Consent 
▪ Failure to report SAEs within 2 business days of knowledge 
▪ Loss of or unaccountable device inventory 
▪ Repeated protocol violations or safety concerns 
▪ Repeated failure to complete Case Report Forms (or inaccurate/incomplete eCRF 
completion) 
▪ Failure to enroll an adequate number of subjects 
▪ The potential benefits are unlikely to outweigh the risks (Futility)  
▪ Or any other reason the Sponsor deems serious enough to require site 
reevaluation/termination.  
If the study is terminated by the Sponsor, the PI(s) will be promptly informed and  must then promptly 
inform the IRB/EC. If the IRB/EC terminates the study, the PI will promptly notif y the Sponsor. This 
notification to the Sponsor must include the explanation for study termination.   
21.13.  Coverage of Subject Expenses 
Subjects will not be compensated for their time during the trial.  The Sponsor ma y provide 
reimbursement for reasonable out-of-pocket costs to treated subjects associated with travel , parking, or 
other expenses associated strictly with completing the protocol requirements of this study t hat would 
not normally be covered under routine medical coverage for the subject9s underlying medical co ndition. 
This will be provided on a case-by-case basis and will require Sponsor (and/or designee) approval. 
21.14.  Clinical Trial Reports 
All information and data generated in association with the study will be held in strict confidence and 
remains the sole property of the Sponsor.  The PI agrees to use this information for the s ole purpose of 
completing the study and for no other purpose without prior approval of the Sponsor.   
All progress reports will be generated and submitted to FDA by the Sponsor in compliance with periodic 
reporting requirements. If requested, all participating PIs and clinical sites should provide assistance to  
the Sponsor regarding the data and any other pertinent information to be included in the study reports. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 80 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
All progress reports submitted to FDA will be summarized by the Sponsor and distributed to ea ch site for 
IRB/EC review, which shall include all relevant feedback and/or approval provided by FDA. 
Upon receipt of the final study data and the final reports from each center, the Sponsor will com plete a 
final study report.  Copies of the final report will be provided to each PI. 
21.15.  Publication Policies 
At the conclusion of the study, a multi-center manuscript led by the national study PI wil l be prepared 
with the assistance of Vesper Medical for publication in a reputable scientific journal. The publi cation of 
the principal results from any single center experience within the trial is not allowed until the 
preparation and publication of the multi-center results as indicated in the Clinical Trial Agreem ent. 
Exceptions to this rule require the prior approval of National PI and Vesper Medical. For the purpos es of 
timely abstract presentation and publication, secondary publications will be delegated to  the 
appropriate principal authors, and final analyses and manuscript review for all multi-center data and/o r 
single-center experience reports will require review from Vesper Medical. 
This study is registered with clinicaltrials.gov (NCT Number Pending). 
21.16.  Medicare Study Criteria 
The study’s results information on all pre-specified outcomes, including negative outcomes, wi ll be 
submitted to ClinicalTrials.gov  not later than one year after the study completion date, where the 
completion date is defined as the date that the final subject was examined or received an interventi on 
for purposes of data collection for the primary outcome measure. Results submission could be d elayed if 
an extension is granted to the results submission deadline; however, the release of all results on pre-
specified outcomes will be hastened if the study is terminated early. 
It is not anticipated that the device under investigation will affect the Medicare populati on any 
differently than subjects in the PIs’ general population for this same condition, includ ing populations 
eligible for Medicare due to age (e.g., 65 years or older), disability, or other eligibil ity status. The 
incidence of chronic venous disease (CVD) increases with age. Advanced manifestations CEAP class 3-6 
disease tend to be poorly tolerated in the geriatric set, particularly after the age of 80 years.34 The 
geriatric population aged 80 years and older with severe manifestations of chronic venous disease face 
diminishing therapeutic options. Self-applied compression is often not possible because of frai lty or 
arthritis. Significant limb swelling diminishes mobility, affects independent living, and precipi tates 
institutionalization. Iliac vein stenting may have a role as it appears to be safe and effective in th is 
advanced stage of life.34 Because the incidence of CVD increases with age the results of this study are 
expected to be generalizable to the Medicare eligible population primarily due to age but not 
necessarily due to disability or other eligibility status. 
 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 81 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 ECONOMIC ANALYSIS  
Vesper Medical, Inc. may collect procedural and reimbursement data (if applicable) from multiple 
sources including but not limited to hospital billing forms and Medicare claims data. Any data co llected 
will be used to perform an economic analysis for the Vesper DUO Venous Stent System. 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 82 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 STUDY DEFINITIONS  
Term Definition 
Adverse Device Effect (ADE) An adverse device effect is defined as any untoward adverse 
event related to the use of an investigational or unintended 
response to a medical device.   
Note 1: This definition includes adverse events resulting from 
insufficient or inadequate Instructions for Use, deployment, 
implantation, installation, or operation, or any malfunction of 
the investigational medical device 
Note 2: This definition includes any event resulting from use 
error or from intentional misuse of the investigational medical 
device. 
Adverse Event (AE) An AE is any untoward medical occurrence, unintended disease 
or injury, or untoward clinical signs (including abnormal 
laboratory findings) in subjects whether or not related to the 
investigational device/procedure. 
Allergic Reaction An allergic reaction characterized by rash, nausea, vomiting, 
upper respiratory congestion, urticaria, shortness-of-breath, 
vasovagal reaction, or general collapse (anaphylaxis). 
Clinically driven Target Lesion 
Reintervention (CD-TLR) Endovascular or surgical procedure for new, recurrent, or 
worsening symptoms and core lab adjudicated >50% stenosis or 
occlusion within the stented segment confirmed by diagnostic 
IVUS 
Clinically driven Target Vessel 
Reintervention (CD-TVR) Endovascular or surgical procedure performed on the target 
vessel for new, recurrent, or worsening symptoms 
Device Deficiency Inadequacy of a medical device related to its identity, quality, 
durability, reliability, safety, or performance, such as 
malfunction, misuse or not observing the IFU, and inadequate 
labeling. 
Device Malfunction Failure of a device to meet its performance specifications or 
otherwise perform as intended.  
Device Success Device Success is defined as: 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 83 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
Term Definition 
• Successful deployment of the DUO Stent(s) at the 
intended target site, AND 
• Successful withdrawal of the delivery catheter(s) from 
the introducer sheath, AND 
• The DUO Stent remaining at the intended deployment 
location through completion of the index procedure as 
determined by the PI 
Duplex Ultrasound (DUS) A form of medical ultrasonography that includes the following 
elements on the same screen (<duplex=) to facilitate 
interpretation 1) B-mode, pulsed Doppler display to visualize the 
structure within a vessel and 2) Color-Doppler display to 
visualize the blood flow and hemodynamics within a vessel. 
Index Procedure The interventional procedure during which the study device is 
advanced through the introducer sheath and the subject is 
enrolled. 
Intent-to-treat (ITT) subjects A subject is defined as an ITT and officially enrolled in the study 
once the DUO Venous Stent System is advanced through the 
introducer sheath.   
 
Lesion Success Lesion success defined as target lesion patency of f50% residual 
diameter or area stenosis of the stented segment at the 
completion of the procedure, as assessed by the core 
laboratory. 
Major Amputation Any above the ankle amputation to the target limb. 
Myocardial Infarction (MI) Q wave MI (QWMI): requires one of the following criteria:   
• Chest pain or other acute symptoms consistent with 
myocardial ischemia and new pathological Q waves in two or 
more contiguous ECG leads  
• New pathologic Q waves in two or more contiguous ECG leads 
and elevation of cardiac enzymes above normal.   
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 84 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
Term Definition 
Non-Q Wave MI (NQWMI): defined as either: elevated CK = 2X 
the laboratory upper limit of normal with the presence of an 
elevated CK-MB (any amount above the laboratory upper limit 
of normal) in the absence of new pathological Q waves or 
elevated CK-MB = 3X the laboratory upper limit of normal in the 
absence of new pathological Q waves.   
Per-protocol (PP) subjects The PP population will be defined as ITT subjects with evaluable 
data that have met the definition for device success, excluding 
subjects with major deviations, such as those who meet criteria 
for a protocol violation(s), as determined by the Sponsor. 
Primary Assisted Patency  Primary assisted patency at 12 months defined as freedom from 
DUS core laboratory adjudicated occlusion or stenosis >50% 
within the stented segment following a  reintervention due to a 
>50% but <100% stenosis. If DUS shows >50% stenosis or 
occlusion, confirmation by diagnostic IVUS is required.  
Primary Efficacy Endpoint Primary patency of stented segment at 12 months defined as 
freedom from: 
▪ Duplex Ultrasound (DUS) core laboratory adjudicated 
occlusion or stenosis >50% within the stented segment. 
If DUS shows >50% stenosis or occlusion, confirmation 
by diagnostic IVUS is required  
▪ CEC adjudicated clinically driven target lesion 
reintervention (CD-TLR) defined as endovascular or 
surgical procedure for new, recurrent, or worsening 
symptoms and >50% stenosis or occlusion within the 
stented segment confirmed by diagnostic IVUS   
Primary Safety Endpoint Freedom from major adverse events (MAEs) at 30 days post 
index procedure, as adjudicated by the Clinical Events 
Committee (CEC) or Core Laboratory, including: 
▪ Device or procedure-related death 
▪ Device or procedure-related bleed at the target 
vessel and/or target lesion or at the access site 
requiring surgical or endovascular intervention or 
blood transfusion g2 units  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 85 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
Term Definition 
▪ Device or procedure-related venous injury occurring 
in the target vessel and/or target lesion location or 
at the access site requiring surgical or endovascular 
intervention 
▪ Major amputation of the target limb  
▪ Clinically significant pulmonary embolism, 
confirmed by CT angiography 
▪ Stent embolization outside of the target vessel 
▪ Presence of new thrombus within the stented 
segment 
Procedural Success Lesion success without the occurrence of major adverse events 
(MAEs) from the time of treatment through to discharge 
Restenosis Reoccurrence of narrowing or blockage of the stented segment. 
Secondary Efficacy Endpoints: ▪ Subject symptom relief via VCSS pain score at 12 
months 
▪ Primary assisted patency at 12 months 
o Defined as freedom from DUS core laboratory 
adjudicated occlusion or stenosis >50% within 
the stented segment following a reintervention 
due to a >50% but <100% stenosis. If DUS shows 
>50% stenosis or occlusion, confirmation by 
diagnostic IVUS is required. 
▪ Secondary patency at 12 months 
o Defined as freedom from DUS core laboratory 
adjudicated occlusion or stenosis >50% within 
the stented segment following a reintervention 
due to 100% occlusion. If DUS shows >50% 
stenosis or occlusion, confirmation by diagnostic 
IVUS is required. 
Secondary Target Lesion Patency Secondary patency at 12 months defined as freedom from DUS 
core laboratory adjudicated occlusion or stenosis >50% within 
the stented segment following a reintervention due to 100% 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 86 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
Term Definition 
occlusion. If DUS shows >50% stenosis or occlusion, 
confirmation by diagnostic IVUS is required. 
Serious Adverse Device Event 
(SADE) A serious adverse device effect (SADE) is defined as an adverse 
device effect (ADE) that results in any of the consequences 
characteristics of a serious adverse event (SAE).  
Serious Adverse Event (SAE) A serious adverse event (SAE) is defined an adverse event that:   
• led to death  
• led to a serious deterioration in the health of the 
subject, that either resulted in: 
o a life-threatening illness or injury, or 
o resulted in a permanent impairment of a body 
structure or a body function, or  
o required in-patient hospitalization or 
prolongation of existing hospitalization, or 
o resulted in medical or surgical intervention to 
prevent life-threatening illness or injury or 
permanent impairment to body structure or a 
body function, or  
o led to fetal distress, fetal death or a congenital 
abnormality or birth defect. 
Note: Planned hospitalization for a pre-existing condition, or a 
procedure required by the investigational plan without serious 
deterioration in health, is not considered a serious adverse 
event.   
Stented Segment The area of vessel treated with the DUO Venous Stent System. 
Study Device Procedure Start/End 
Time Start: The time the first DUO Venous Stent System is advanced 
through the introducer sheath                                                                    
End: The time of withdrawal of last post-DUO Stent PTA balloon 
catheter 
Target Lesion Patency  Primary patency of the stented segment at 12 months defined 
as freedom from: 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 87 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
Term Definition 
▪ Duplex Ultrasound (DUS) core laboratory adjudicated 
occlusion or stenosis >50% within the stented segment. 
If DUS shows >50% stenosis or occlusion, confirmation 
by diagnostic IVUS is required. 
▪ CEC adjudicated clinically driven target lesion 
reintervention (CD-TLR) defined as endovascular or 
surgical procedure for new, recurrent, or worsening 
symptoms and >50% stenosis or occlusion within the 
stented segment confirmed by diagnostic IVUS   
Target Lesion Reintervention (TLR)  Any reintervention (endovascular or surgical) to the target 
lesion(s) occurring after the index procedure through the 36-
month subject final visit. 
Target Vessel  The vessel location(s) containing the obstructive lesion.  
Presence of unilateral, non-malignant venous obstruction of the 
common femoral vein (CFV), external iliac vein (EIV), common 
iliac vein (CIV) , or any combination thereof, defined as a g50% 
reduction in target vessel lumen diameter and confirmed by 
venographic or IVUS imaging. The cranial point of the 
obstruction may extend to the iliac vein confluence of the 
inferior vena cava (IVC) and the caudal point may be 2mm above 
either the inflow of the deep femoral (or profunda) or the lesser 
trochanter, whichever is most cranial. 
Target Vessel Reintervention (TVR)  Any reintervention (endovascular or surgical) to the target 
vessel(s) occurring after the index procedure through the 36-
month subject final visit. 
Unanticipated Adverse Device 
Event (UADE) A UADE is defined as any serious adverse effect on health or 
safety, or any life-threatening problem or death caused by, or 
associated with, a device, if that effect, problem, or death was 
not previously identified in nature, severity, or degree of 
incidence in the investigational plan or application (including a 
supplementary plan or application), or any other unanticipated 
serious problem associated with a device that relates to the 
rights, safety, or welfare of subjects. 
Unplanned Procedure A procedure that was not planned at the time of subject 
enrollment.  
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 88 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 
 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 89 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 REFERENCES  
 
1 Mahnken AH, Thomson K, de Haan M, O9Sullivan GJ. CIRSE standards of practice guidelines o n iliocaval stenting. 
Cardiovasc Intervent Radiol 2014; 37(4):889-97. 
2 Milinis K, Thapar A, Shalhoub J, Davies AH. Antithrombotic therapy following veno us stenting: international 
Delphi consensus. Eur J Vasc Endovasc Surg 2018; 55(4):537-44. 
3 Raju S, NeglØn P, Carr-White PA, Fredericks R, Devidas M. Ambulatory ve nous hypertension: component analysis 
in 373 limbs. Vasc Surg 1999; 33:257-67. 
4 NeglØn P, Thrasher TL, Raju S. Venous outflow obstruction: an underestimated contributor to chronic venous 
disease. J Vasc Surg 2003; 38(5):879-85. 
5 Chung JW, Yoon CJ, Jung SI, Kim HC, Lee W, Kim YI, et al.  Acute iliofemoral deep vein thro mbosis: evaluation of 
underlying anatomic abnormalities by spiral CT venography.  J Vasc Interv Radiol  2004; 15(3):249-56. 
6 Mahnken AH, Thomson K, de Haan M, O9Sullivan GJ. CIRSE standards of practice guidelines o n iliocaval stenting. 
Cardiovasc Intervent Radiol 2014; 37(4):889-97. 
7 Milinis K, Thapar A, Shalhoub J, Davies AH. Antithrombotic therapy following veno us stenting: International 
Delphi consensus. Eur J Vasc Endovasc Surg 2018; 55(4):537-44. 
8 Razavi MK, Jaff MR, Miller LE. Safety and effectiveness of stent placement for ili ofemoral outflow obstruction: 
Systematic review and meta-analysis. Circ Cardiovasc Interv 2015; 8:e002772. 
9 NeglØn P, Hollis KC, Raju S. Combined saphenous ablation and iliac sten t placement for complex severe chronic 
venous disease. J Vasc Surg 2006; 44(4):828-33. 
10 Milinis K, Thapar A, Shalhoub J, Davies AH. Antithrombotic therapy following veno us stenting: international 
Delphi consensus. Eur J Vasc Endovasc Surg 2018; 55(4):537-44. 
11 Razavi MK, Jaff MR, Miller LE. Safety and effectiveness of stent placement for ili ofemoral outflow obstruction: 
Systematic review and meta-analysis. Circ Cardiovasc Interv 2015; 8:e002772. 
12 Zollikofer CL, Largiader I, Bruhlmann WF, Uhlschmid GK, Marty AH.  Endovascular stenti ng of veins and grafts:  
preliminary clinical experience.  Radiology 1988; 167:707-12; Antonucci F, Salomonowitz  E, Stuckmann G, Stiefel 
M, Largiader J, Zollikofer CL.  Placement of venous stents: clinical experience with  a self-expanding prosthesis.  
Radiology 1992; 183(2):493-97 
13 NeglØn P, Hollis KC, Raju S. Combined saphenous ablation and iliac sten t placement for complex severe chronic 
venous disease. J Vasc Surg 2006; 44(4):828-33. 
14 NeglØn P, Thrasher TL, Raju S. Venous outflow obstruction: An underestimated contributor to chronic venous 
disease. J Vasc Surg 2003; 38(5):879-85 
15 Mahnken AH, Thomson K, de Haan M, O9Sullivan GJ. CIRSE standards of practice guidelines o n iliocaval stenting. 
Cardiovasc Intervent Radiol 2014; 37(4):889-97. 
16 American College of Phlebology. Management of Obstruction of the Femoroiliocav al Venous System. 
http://www.phlebology.org/wp-content/uploads/2015/10/Management-of-Obstruction-of-th e-Femoroiliocaval-
Venous-System-Guidelines.pdf.  
17 Razavi MK, Jaff MR, Miller LE. Safety and effectiveness of stent placement for ili ofemoral outflow obstruction: 
Systematic review and meta-analysis. Circ Cardiovasc Interv 2015; 8:e002772. 
18 Oguzkurt L, Tercan F, Pourbagher MA, Kizilkilic O, Turkoz R, Boyvat F. Computed tomography findings i n 10 cases 
of iliac vein compression (May-Thurner) syndrome.  Eur J Radiol 2005; 55(3):421-5;  Wahlgren CM, Wahlberg E, 
Olofsson P.  Endovascular treatment in postthrombotic syndrome. Vasc Endovascul ar Surg 2010; 44(5):356-60. 
19 Alhadad A, Lolbel T, Herbst A, Holst J, Alhadad H, Gottsater A.  Iliocaval vein sten ting:  Long term survey of 
postthrombotic symptoms and working capacity.  J Thromb Thrombolysis 2011; 31(2):211- 16. 
20 NeglØn P, Hollis KC, Olivier J, Raju S.  Stenting of the venous outflow in chro nic venous disease: long-term stent 
related outcome, clinical, and hemodynamic result.  J Vasc Surg 2007; 46(5):979-90. 
 
 VIVID Study Clinical Trial Protocol – DUO™ Venous Stent System  
V-CA-0001  
   
 
Page 90 of 90 
Protocol Number: V-CA-0001  Protocol Version: Rev. E April 23, 2021 
 
 
 
21 Hurst DR, Forauer AR, Bloom JR, Greenfield LJ, Wakefield TW, Wil liams DM. Diagnosis and endovascular 
treatment of iliocaval compression syndrome. J Vasc Surg. 2001; 34(1):106-13. 
22 Nazarian GK, Austin WR, Wegryn SA, Bjarnason H, Stackhouse DJ, Castanes a-Zuniga WR, et al. Venous 
recanalization by metallic stents after failure of balloon angioplasty or surgery: four -year experience. Cardiovasc 
Intervent Radiol. 1996; 19(4):227-33. 
23 O9Sullivan  GJ, Semba CP, Bittner CA, Kee ST, Razavi MK, Sze DY, et al. Endovas cular management of iliac vein 
compression (May-Thurner) syndrome. J Vasc Interv Radiol. 2000; 11(7):823-36. 
24 Binkert CA, Schoch E, Stuckmann G, Largiader J, Wigger P, Schoepke W, et a l. Treatment of pelvic venous spur 
(May-Thurner syndrome) with self-expanding metallic endoprostheses. Cardi ovasc Intervent Radiol. 1998; 
21(1):22-26. 
25 Nazarian GK, Bjarnason H, Dietz CA Jr, Bernadas CA, Hunter DW. Iliofem oral venous stenosis: effectiveness of 
treatment with metallic endovascular stents. Radiology. 1996; 200(1):193-99. 
26 Lamont JP, Pearl GJ, Patetsios P, Warner MT, Gable DR, Garrett W, et al. Prospective evaluation of endoluminal 
venous stents in the treatment of the May-Thurner syndrome. Ann Vasc Surg. 200 2; 16(1):61-64. 
27 Razavi M, Marston W, Black S, Bentley D, NeglØn P.  The initial report on 1-year outcome s of the feasibility study 
of the VENITI VICI VENOUS STENT in symptomatic iliofemoral venous obstruction.  J Vasc Surg Venous Lymphat 
Disord. 2018; 6(2):192-200. 
28 O9Sullivan G, Sheehan J, Lohan D, McCann -Brown JA.  Iliofemoral venous stenting extending into the femoral 
regions:  initial clinical experience with the purpose-designed Zilver Vena stent.   J Cardiovasc Surg. 2013 April; 
54(2):255-61. 
29 NeglØn P, Hollis KC, Olivier J, Raju S. Stenting of the venous outflow in chroni c venous disease: long-term stent-
related outcome, clinical, and hemodynamic result. J Vasc Surg. 2007; 45(6):979-90. 
30 NeglØn P, Raju S.  Balloon dilation and stenting of chronic iliac vein obstruction:  t echnical aspects and early 
clinical outcome.  J Endovasc Ther 2000; 7(2):79-91. 
31 Mahnken AH, Thomson K, de Haan M, O9Sullivan GJ. CIRSE standards of practice guidelines o n iliocaval stenting. 
Cardiovasc Intervent Radiol 2014; 37(4):889-97. 
32 Mahnken AH, Thomson K, de Haan M, O9Sullivan GJ. CIRSE standards of practi ce guidelines on iliocaval stenting. 
Cardiovasc Intervent Radiol 2014; 37(4):889-97. 
33 Lichtenberg M, de Graaf R, Erbel C.  Standards for recanalization of chronic venous outflow ob structions. Vasa. 
2018; 47(4):259-66. 
34 Raju S, Ward M. Utility of iliac vein stenting in elderly population older than 80 y ears. J Vasc Surg Venous 
Lymphat Disord. 2015; 3(1):58-63. 